Ophthalmic compositions comprising sterilised lifitegrast and semifluorinated alkanes
Gamma irradiation of lifitegrast with semifluorinated alkanes creates a stable, preservative-free ophthalmic composition for treating dry eye disease, addressing the need for improved sterility and reducing environmental impact.
Patent Information
- Application Number
- PCT/EP2026/062993
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-27
- Filing Date
- 2026-05-05
- Publication Date
- 2026-11-12
AI Technical Summary
There is a need for improved, stable, sterile ophthalmic compositions for treating dry eye disease that are free or substantially free of potentially irritating antioxidants and preservatives, and require environmentally friendly methods for sterilization of lifitegrast during manufacture.
The use of gamma irradiation to sterilize lifitegrast or its pharmaceutically acceptable salt, combined with at least one semifluorinated alkane such as perfluorohexyloctane, to create a stable, preservative-free ophthalmic composition that does not require additional ingredients, allowing for multi-dose formats and reducing environmental impact.
The resulting composition is sterile, stable, and effective in treating dry eye disease with reduced ocular irritation, while minimizing waste and cost, and can be administered in a multi-dose format.
Smart Images

Figure EP2026062993_12112026_PF_FP_ABST
Abstract
Description
OPHTHALMIC COMPOSITIONS COMPRISING STERILISED LIFITEGRAST AND SEMIFLUORINATED ALKANES
[0001] This application claims the benefit of United States Patent Application 63 / 800,746, filed May 6th 2025, and European Patent Application 25178921.0, filed 27th May 2025, the complete contents of which are incorporated herein by reference.
[0002] The invention relates to the sterilisation of lifitegrast or a pharmaceutically acceptable salt thereof for inclusion in ophthalmic compositions which also include a semifluorinated alkane, such as perfluorohexyloctane (F6H8).BACKGROUND
[0003] Keratoconjunctivitis sicca, also known as dry eye disease (DED), is a multifunctional disorder of the tear film and ocular surface which results in discomfort, visual disturbance, and often even in ocular surface damage. Secondary diseases whose development may be triggered by DED include filamentary keratitis, microbial keratitis, corneal neovascularisation, and ocular surface keratinisation. Two major categories of DED are distinguished today, which are aqueous-deficient DED and evaporative DED. These conditions are not necessarily mutually exclusive.
[0004] Within the class of aqueous-deficient forms of DED, two major subtypes are differentiated, Sjogren and non-Sjdgren. Evaporative DED is associated with increased evaporative loss of the tear film and can develop as a result of diverse root causes including meibomian gland disease, eyelid aperture disorders, blink disorders (as in Parkinson disease) or ocular surface disorders (as in allergic conjunctivitis).
[0005] Typically, ophthalmic compositions for treatment of DED are administered as eye drops, with one or more drops of the composition being applied to an eye of the subject suffering from or susceptible to the disease one or more times per day, although the frequency of administration of such compositions may be dependent on multiple factors, including the makeup of the particular composition.
[0006] Lifitegrast (the active ingredient of Xiidra®) is a small molecule lymphocyte function-associated antigen 1 (LFA-1) antagonist that has been approved for the treatment of signs and symptoms of DED. It has the following structure:
[0007] Despite the success of Xiidra in meeting the needs of many patients, there remains a need for improved DED treatments, particularly those that are stable, sterile, and having lesser concentrations of (or even substantially free of) potentially irritating antioxidants and / or preservatives.
[0008] Disclosed herein and in PCT / EP2024 / 082568 are improved, stable ophthalmic compositions comprising (a) lifitegrast; and (b) at least one semifluorinated alkane. These compositions may be preservative-free and / or free of antioxidants. Without wishing to be bound by theory, it is believed that, not only does the at least one semifluorinated alkane provide its own ocular disorder treatment and / or prevention effect (thus intersecting the disease cycle with effects on both inflammation and tear evaporation), but it also acts as a stable, non-aqueous vehicle or carrier for the lifitegrast. The non-aqueous nature also allows for the reduction or elimination of the need for additional ingredients, such as antioxidants and / or preservatives. This circumvents the potential for ocular damage from preservatives, which is particularly high among patients suffering from chronic diseases, such as dry eye disease, that require daily eye drop instillations for periods of years to decades. Moreover, the ability to prepare a product which does not need an extrinsic preservative means that it can be provided in a multi-dose format, which reduces the waste and cost associated with packaging materials. The unique combination of the lifitegrast and the at least one semifluorinated alkane thus provides improved, stable ophthalmic compositions. Furthermore, the compositions can achieve similar ocular exposure as aqueous lifitegrast compositions but with only one third of the dose.
[0009] It is important that ophthalmic compositions are sterile to prevent infections in the eye after administration. The sterility of these compositions is strictly regulated by health authorities. Therefore, during manufacture, an ophthalmic composition must be sterilised, or its components must be separately sterilised and mixed aseptically. The manufacture of Xiidra involves sterile filtration of the ophthalmic solution comprising lifitegrast before it is aseptically filled into a sterile container closure system. Various methods for the sterilisation of active ingredients are known, including sterile filtration, dry heat sterilisation, steam sterilisation, gas sterilisation (e.g. using ethylene oxide), and radiation sterilisation. However, depending on the nature of the composition, not all methods are feasible without damaging the active ingredient. Furthermore, the emission of ethylene oxide from gas sterilisation is associated with environmental damage and increased health risks.
[0010] There is a need for sterile ophthalmic compositions comprising lifitegrast and at least one semifluorinated alkane, and for feasible environmentally friendly methods for sterilisation of lifitegrast during the manufacture of these compositions.SUMMARY OF THE INVENTION
[0011] The inventors have found that lifitegrast or a pharmaceutically acceptable salt thereof may be advantageously sterilised by gamma irradiation during the manufacture of ophthalmic compositions comprising (a) lifitegrast or a pharmaceutically acceptable salt thereof, and (b) at least one semifluorinated alkane, without adversely affecting the safety and efficacy of the composition; for example, there is no formation of species that are toxic or that inhibit the activity of the lifitegrast or the at least one semifluorinated alkane. Thus, disclosed herein are processes for preparing an ophthalmic composition comprising (a) lifitegrast or a pharmaceutically acceptable salt thereof and (b) at least one semifluorinated alkane, the process comprising: (i) sterilising lifitegrast or a pharmaceutically acceptable salt thereof using gamma irradiation; and (ii) mixing the sterilised lifitegrast or a pharmaceutically acceptable salt thereof with at least one semifluorinated alkane. Preferably, the ophthalmic composition consists essentially of (a) lifitegrast or a pharmaceutically acceptable salt thereof and (b) perfluorohexyloctane (F6H8). Therefore, the process preferably comprises (i) sterilising lifitegrast or a pharmaceutically acceptable salt thereof using gamma irradiation; and (ii) mixing the sterilised lifitegrast or a pharmaceutically acceptable salt thereof with perfluorohexyloctane (F6H8).
[0012] Further disclosed herein are ophthalmic compositions prepared by such processes. The inventors have determined the structure of specific compounds related to lifitegrast that are formed during the gamma sterilisation process. The safety of these compounds was assessed, and all were found to be safe. Thus, the inventors have found that sterile, stable ophthalmic compositions may be provided comprising (a) lifitegrast or a pharmaceutically acceptable salt thereof, (b) at least one semifluorinated alkane, and (c) at least one compound selected from the following compounds:Compound A1:Compound A2:Compound B:Compound C1:Compound C2:Compound C3:Compound D:and pharmaceutically acceptable salts thereof.
[0013] The above compounds are useful standards for assessing the purity of lifitegrast sterilised by gamma irradiation.
[0014] Preferably, the composition consists essentially of (a) lifitegrast or a pharmaceutically acceptable salt thereof, (b) at least one semifluorinated alkane, and (c) at least one compound selected from: Compound A1, Compound A2, Compound B, Compound C1, Compound C2, Compound C3, Compound D, and pharmaceutically acceptable salts thereof. More preferably, the composition consists essentially of (a) lifitegrast or a pharmaceutically acceptable salt thereof, (b) at least one semifluorinated alkane, and (c):(i) at least one of Compound A1, Compound A2, and pharmaceutically acceptable salts thereof;(ii) Compound B or a pharmaceutically acceptable salt thereof;(iii) at least one of Compound C1, Compound C2, Compound C3, and pharmaceutically acceptable salts thereof; and(iv) Compound D or a pharmaceutically acceptable salt thereof.
[0015] It has been surprisingly found that a composition consisting essentially of these ingredients is sterile, stable and provides improved delivery of lifitegrast relative to an aqueous solution of lifitegrast. Moreover, limiting the composition to these ingredients simplifies manufacture of the composition, whilst the composition is effective for treating ocular disorders such as dry eye disease without the addition of any further compounds to the eye.
[0016] The composition may comprise from about 2% (w / w) to about 6% (w / w), for example about 2.5% (w / w) or about 5% (w / w), lifitegrast or a pharmaceutically acceptable salt thereof, and the at least one semifluorinated alkane may be perfluorohexyloctane (F6H8). Preferably, the compositions are non-aqueous liquid compositions (i.e., substantially free of water). Component (c) may be present at up to about 0.5% by weight of the total composition, for example from about 0.0001% to about 0.5% by weight of the total composition.
[0017] Further disclosed herein are methods for the treatment and / or temporary prevention of at least one ocular disorder, preferably dry eye disease, comprising administering to a patient in need thereof an effective amount of an ophthalmic composition comprising components (a) to (c).
[0018] Similarly, provided are: ophthalmic compositions comprising components (a) to (c), for use in a method for the treatment or temporary prevention of at least one ocular disorder, preferably dry eye disease; and the use of lifitegrast or a pharmaceutically acceptable salt thereof and at least one semifluorinated alkane in the manufacture ofan ophthalmic composition comprising components (a) to (c) for the treatment or temporary prevention of at least one ocular disorder, preferably dry eye disease.
[0019] Further disclosed herein are processes for preparing an ophthalmic composition comprising (a) I if itegrast or a pharmaceutically acceptable salt thereof and (b) at least one semifluorinated alkane, the process comprising: (i) obtaining a sample of a batch of sterilised lifitegrast or a pharmaceutically acceptable salt thereof; (ii) determining that the total amount of Compound A1, Compound A2, Compound B, Compound C1, Compound C2, Compound C3, and Compound D, and pharmaceutically acceptable salts thereof present in the sample is about 3 mol% or less relative to the amount of lifitegrast or a pharmaceutically acceptable salt thereof, preferably wherein the total amount is determined by liquid chromatography such as high performance liquid chromatography (HPLC) or ultra performance liquid chromatography (LIPLC); and (iii) mixing the batch of sterilised lifitegrast or a pharmaceutically acceptable salt thereof with at least one semifluorinated alkane.
[0020] Further disclosed herein are processes for assessing a batch of an ophthalmic composition comprising (a) lifitegrast or a pharmaceutically acceptable salt thereof and (b) at least one semifluorinated alkane, the process comprising: (i) obtaining a sample of the batch of ophthalmic composition; (ii) determining the total amount of Compound A1, Compound A2, Compound B, Compound C1, Compound C2, Compound C3, and Compound D, and pharmaceutically acceptable salts thereof present in the sample, preferably wherein the total amount is determined by liquid chromatography such as high performance liquid chromatography (HPLC) or ultra performance liquid chromatography (LIPLC); and (iii) validating the batch of ophthalmic composition only if the total amount of said compounds is about 3 mol% or less relative to the amount of lifitegrast or a pharmaceutically acceptable salt thereof.
[0021] The invention also provides a compound selected from Compound A1, Compound A2, Compound B, Compound C1, Compound C2, Compound C3, and Compound D, and pharmaceutically acceptable salts thereof.
[0022] These and other features, aspects, and advantages of the disclosure will be apparent from a reading of the following.Definitions
[0023] Definitions of certain terms as used in this application are provided below. Unless defined otherwise, all technical and scientific terms used herein have the normal and common meaning that would be commonly understood by one of ordinary skill in the art to which this disclosure belongs.
[0024] As used herein, the term “about” means approximately, in the region of, roughly, or around. The term “about” in relation to a numerical value x is optional and means, for example, x ± 5%. Numerical values disclosed with the term “about” include the specifically identified value. For example, “about 100” means a number ranging from 95 to 105, including 95, 100, and 105.
[0025] As used herein, “administration” of a compound or composition to a patient refers to any route of introducing or delivering the compound or composition to a subject. Administration includes self-administration and the administration by another.
[0026] As used herein, a “condition,” “disorder,” or “disease” refers to any unhealthy or abnormal state.
[0027] As used herein, an “effective amount” or “effective dose” refers to an amount of a compound or composition that treats and / or temporarily prevents, upon single or multiple dose administration, a patient suffering from a disorder, disease, or condition. An effective amount can be determined by the attending diagnostician through the use of known techniques and by observing results obtained under analogous circumstances. In determining the effective amount, a number of factors are considered by the attending diagnostician, including, but not limited to: the species of patient; its size, age, and general health; the specific condition, disorder, or disease involved; the degree of or involvement or the seventy of the condition, disorder, or disease, the response of the individual patient; the particular compound administered; the mode of administration; the bioavailability characteristics of the preparation administered; the dose regimen selected; the use of concomitant medication; and other relevant circumstances.
[0028] As used herein, a composition is “free” of a component when it comprises no detectable amount of the component.
[0029] As used herein, the term “consists essentially of” means that, in addition to the mandatory ingredients, specific further ingredients can be present, namely those not materially affecting the essential characteristics of the composition or component in question. Compositions or components herein which “consist essentially of’ the specified ingredients may consist only of the specified ingredients, with no other ingredients present (in which case the composition “consists of” the specified ingredients).
[0030] As used herein, the terms “patient,” “subject,” “individual,” and the like, as used herein, are interchangeable and refer to any animal, which may be a human or a non-human animal. Compositions disclosed herein are particularly suited to use in humans and so the patient is preferably a human.
[0031] As used herein, the terms “prevention” of or “preventing” a disorder, disease, or condition refers to reducing the severity and / or the occurrence of the disorder, disease, or condition in a treated sample relative to an untreated control sample, and includes delaying onset and / or progression of the disorder or condition relative to the untreated control sample.
[0032] As used herein, the term “ocular disorder” refers to any of the signs, symptoms, and / or underlying cause(s) of any physiological disorder that affects the eye or vision.
[0033] As used herein, the term “particle diameter” refers to the equivalent spherical diameter (esd), i.e., the diameter of a sphere having the same volume as a given particle. The terms “Dn” and “Dnparticle diameter” refer to the diameter below which n% by volume of the particle population is found. Thus, the terms “Dso” and “Dso particle diameter” refer to the volume-based median particle diameter below which 50% by volume of the particle population is found, and the terms “D90” and “D90 particle diameter” refer to the particle diameter below which 90% by volume of the particle population is found. Particle diameters can be determined by laser diffraction, for example in accordance with U.S. Pharmacopeia chapter <429>, 2024. The particle diameter of I ifitegrast or a pharmaceutically acceptable salt thereof, such as the D90 or D50 particle diameter, in at least one semifluorinated alkane may be determined using routine laser diffraction methods. In particular, the particle diameter may be determined using a light diffraction particle analyser (e.g., Horiba LA-960) preferably equipped with a circulation system (e.g., Horiba MiniFlow), for example using the LA-960 for Windows V8.40 software. The particle size may be determined using Mie theory, for example using a real and imaginary refractive index of 1.643 and 0.1 respectively. Preferably, a dispersant, such as 0.1% (w / w) sorbitan monooleate (e.g. Span® 80) in heptane, may be added to improve the separation of the lifitegrast particles. Optionally, the mixture of lifitegrast suspension and dispersant consists of about 1% (w / w) suspension and about 99% (w / w) dispersant.
[0034] As used herein, a “pharmaceutically acceptable excipient” refers to a carrier or an excipient that is useful in preparing a pharmaceutical composition. For example, a pharmaceutically acceptable excipient is generally safe and includes carriers and excipients that are generally considered acceptable for mammalian pharmaceutical use. As a non-limiting example, pharmaceutically acceptable excipients may be solid, semi-solid, or liquid materials which, in the aggregate, can serve as a vehicle or medium for active ingredients. Some examples of pharmaceutically acceptableexcipients are found in Remington’s Pharmaceutical Sciences and Rowe’s Handbook of Pharmaceutical Excipients and include diluents, vehicles, carriers, ointment bases, binders, stabilizing agents, preservatives, solvents, suspending agents, and others. In the ophthalmic compositions of the present disclosure, the at least one semifluorinated alkane is not a “pharmaceutically acceptable excipient” because it provides its own ocular disorder treatment and / or prevention effect.
[0035] As used herein, a container closure system is the sum of packaging components that collectively contain the ophthalmic composition. For example, the container closure system may consist of a bottle, a droplet-forming outlet, and a screw cap. Alternatively, the container closure system may consist of a vial, which is integrally formed with a droplet forming outlet, and a cap that forms an interference fit with the droplet forming outlet.
[0036] As used herein, a bottle is a container for storing and dispensing a liquid ophthalmic composition having a neck, a body that is wider than the neck, and a base that allows the bottle to stand upright on a flat surface. The body of the bottle is squeezable by hand to dispense the composition through the neck.
[0037] As used herein, a vial is a container for storing and dispensing a liquid ophthalmic composition. It is squeezable by hand to dispense the composition through an outlet. The vial typically is or forms part of a multi-dose container closure system. The vial may comprise a tapered section that is snapped open to form the dropletforming outlet. The vial may comprise a neck at one end, with a circular cross section, and may be crimped at the other end to form a seal, giving an elliptical cross-section through the body of the vial. Unlike a bottle, a vial typically lacks a base that allows it to stand upright on a flat surface.
[0038] As used herein, a “pharmaceutically acceptable salt” is a salt that is suitable for use in contact with tissues of humans without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. Pharmaceutically acceptable salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N+(Ci-4alkyl)4 salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Examples of pharmaceutically acceptable acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceuticallyacceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate, and aryl sulfonate.
[0039] As used herein, a composition is “stable” if less than about 10% of lifitegrast within the composition is degraded (i.e. , at least 90% of the lifitegrast is intact) after being stored at about 25 °C for 10 weeks, as measured by high-performance liquid chromatography (HPLC) or an equivalent appropriate technique such as that within the U.S. Pharmacopeia, preferably by HPLC.
[0040] As used herein, a composition is “sterile” if it has a microbial bioburden of less than or equal to 0.1 CFU / ml, as measured by a standard plate count method or an equivalent appropriate technique such as that within the U.S. Pharmacopeia.
[0041] As used herein, a substance, composition, or container closure system is “sterilised” if the substance, composition, or container closure system has been subjected to a sterilisation process , especially sterilisation by gamma irradiation.
[0042] As used herein, the term “treat,” “treating,” or “treatment,” when used in connection with a disorder or condition, includes any effect, e.g., lessening, reducing, modulating, ameliorating, or eliminating, that results in the improvement of the disorder or condition. Improvements in or lessening the seventy of any symptom of the disorder or condition can be readily assessed according to standard methods and techniques known in the art.
[0043] As will be understood by one of ordinary skill in the art, each range disclosed herein includes all possible subranges as well as individual numerical values within that range, including endpoints. As a non-limiting example, a range of “0.001% to 0.02%” includes the endpoints of 0.001% and 0.02%, and would be understood to specifically disclose subranges such as “0.004% to 0.01%,” “0.005% to 0.02%,” etc.,as well as all individual numbers within the disclosed range, for example, 0.001%, 0.004%, 0.005%, 0.01%, 0.02%, etc.
[0044] Any percentage concentration values disclosed herein are on a weight-per-weight (w / w) basis unless otherwise specified.
[0045] Unless specifically stated, a process or method comprising a step of mixing two or more components does not require any specific order of mixing. Thus, components can be mixed in any order. Where there are three components then two components can be combined with each other, and then the combination may be combined with the third component, etc.
[0046] The various steps of the methods or processes herein may be carried out at the same time or at different times, in the same or different geographical locations, e.g., countries, and by the same or different people or entities.DETAILED DESCRIPTION OF THE INVENTIONSterilisation methods
[0047] The invention provides a process for preparing an ophthalmic composition comprising (a) I ifitegrast or a pharmaceutically acceptable salt thereof and (b) at least one semifluorinated alkane, wherein the process comprises: (i) sterilising lifitegrast or a pharmaceutically acceptable salt thereof using gamma irradiation; and (ii) mixing the sterilised lifitegrast or a pharmaceutically acceptable salt thereof with at least one semifluorinated alkane, for example by aseptically mixing the sterilised lifitegrast or a pharmaceutically acceptable salt thereof with at least one semifluorinated alkane. Preferably, the process is a process for preparing an ophthalmic composition consisting essentially of (a) lifitegrast or a pharmaceutically acceptable salt thereof and (b) perfluorohexyloctane, wherein the process comprises (i) sterilising lifitegrast or a pharmaceutically acceptable salt thereof using gamma irradiation; and (ii) mixing the sterilised lifitegrast or a pharmaceutically acceptable salt thereof with perfluorohexyloctane. Gamma sterilisation has been found to be a feasible and environmentally friendly method of sterilising lifitegrast without adversely affecting the safety and efficacy of an ophthalmic composition comprising lifitegrast and a semifluorinated alkane. It will be understood by a person skilled in the art that sterilising a substance, such as lifitegrast, does not involve subjecting it to a process that causes high levels of degradation as this would adversely affect its activity. Thus, preferably, the amount of lifitegrast or a pharmaceutically acceptable salt thereof after sterilisation is about 97 mol% or more of the amount of lifitegrast or a pharmaceutically acceptable salt thereof before sterilisation, more preferably about 98 mol% or more of the amount of lifitegrast or a pharmaceutically acceptable salt thereof before sterilisation.
[0048] The lifitegrast or a pharmaceutically acceptable salt thereof may be exposed to a dose of gamma radiation of from about 10 to about 50 kGy, for example, from about 15 to about 40 kGy, or from about 30 to about 40 kGy.
[0049] The process may comprise (i) sterilising lifitegrast or a pharmaceutically acceptable salt thereof using gamma irradiation; (ii) sterilising at least one semifluorinated alkane, preferably by sterile filtration; and (iii) aseptically mixing the sterilised lifitegrast or a pharmaceutically acceptable salt thereof with the at least one sterilised semifluorinated alkane.
[0050] The process may further comprise ball-milling the mixture of sterilised lifitegrast or a pharmaceutically acceptable salt thereof and at least one sterilised semifluorinated alkane, preferably wherein the process comprises subjecting the sterilised lifitegrast or a pharmaceutically acceptable salt thereof to ball-milling to obtain a D90 particle diameter of lifitegrast or a pharmaceutically acceptable salt thereof of about 10 pm or less.
[0051] The process may further comprise aseptically filling the mixture into a package, such as a multi-dose package.
[0052] Although less preferred than sterilising the lifitegrast or a pharmaceutically acceptable salt thereof using gamma irradiation prior to mixing with a semifluorinated alkane, the process may instead comprise mixing lifitegrast or a pharmaceutically acceptable salt thereof and at least one semifluorinated alkane to form a suspension, and then sterilising the suspension using gamma irradiation. Following gamma irradiation, the suspension may then be subjected to ball milling, as described above. All of the properties of the process and the composition described herein in the context of a process comprising mixing sterilised lifitegrast or a pharmaceutically acceptable salt thereof with at least one semifluorinated alkane (e.g. the amounts of the ingredients in the composition, the nature of the semifluorinated alkane, etc) apply equally to the process of mixing the lifitegrast or a pharmaceutically acceptable salt thereof with at least one semifluorinated alkane and then sterilising the suspension using gamma irradiation.
[0053] As described above, Compound A1, Compound A2, Compound B, Compound C1, Compound C2, Compound C3, and Compound D may be formed during gamma sterilisation and are useful standards for assessing the purity of lifitegrast sterilised by gamma irradiation. In an ophthalmic composition, the total concentration of these compounds (i.e., the sum of Compounds A1, A2, B, C1, C2, C3 and D) relative to lifitegrast should be about 3 mol% or less to reduce the risk of these compounds affecting efficacy of the ophthalmic composition.
[0054] Thus, the invention provides a process of preparing an ophthalmic composition, as defined herein, comprising (a) lifitegrast or a pharmaceutically acceptable salt thereof and (b) at least one semifluorinated alkane, the process comprising: (i) obtaining a sample of a batch of sterilised lifitegrast or a pharmaceutically acceptable salt thereof; (ii) determining that the total amount of Compound A1, Compound A2, Compound B, Compound C1, Compound C2, Compound C3, and Compound D, and pharmaceutically acceptable salts thereof present in the sample is about 3 mol% (mole percent) or less relative to the amount of lifitegrast or a pharmaceutically acceptable salt thereof; and (iii) mixing the batch of sterilised lifitegrast or a pharmaceutically acceptable salt thereof with at least one semifluorinated alkane, preferably at least one sterilised semifluorinated alkane.
[0055] The invention also provides processes for assessing a batch of an ophthalmic composition, as defined herein, comprising (a) lifitegrast or a pharmaceutically acceptable salt thereof and (b) at least one semifluorinated alkane, the process comprising: (i) obtaining a sample of the batch of ophthalmic composition; (ii) determining the total amount of Compound A1, Compound A2, Compound B, Compound C1, Compound C2, Compound C3, and Compound D, and pharmaceutically acceptable salts thereof present in the sample; and (iii) validating the batch of ophthalmic composition only if the total amount of said compounds is about 3 mol% or less relative to the amount of lifitegrast or a pharmaceutically acceptable salt thereof.
[0056] The amount of the compound selected from Compound A1, Compound A2, Compound B, Compound C1, Compound C2, Compound C3, Compound D, and pharmaceutically acceptable salts thereof may be determined by liquid chromatography, such as high performance liquid chromatography (HPLC) or ultra performance liquid chromatography (LIPLC).
[0057] Preferably, the ophthalmic composition prepared using these processes is a composition as described below.Ophthalmic compositions
[0058] The ophthalmic compositions of the present disclosure comprise or consist essentially of (a) lifitegrast or a pharmaceutically acceptable salt thereof, (b) at least one semifluorinated alkane, such as perfluorohexyloctane (F6H8), and (c) at least one compound selected from: Compound A1, Compound A2, Compound B, Compound C1, Compound C2, Compound C3, Compound D, and pharmaceutically acceptable salts thereof. The compounds listed as component (c) are specific compounds generated by gamma sterilisation of lifitegrast and their safety has been verified. Theophthalmic compositions may be used to treat and / or temporarily prevent an ocular condition, such as dry eye disease. The ophthalmic compositions are stable for each active ingredient, provide efficient drug delivery, and are well tolerated by the eye.
[0059] The combined weight of the (a) I ifitegrast or a pharmaceutically acceptable salt thereof, (b) at least one semifluorinated alkane, and (c) at least one compound selected from: Compound A1, Compound A2, Compound B, Compound C1, Compound C2, Compound C3, Compound D, and pharmaceutically acceptable salts thereof may be more than 99.5% (w / w) of the total weight of the ophthalmic composition.
[0060] The preferred ophthalmic compositions may consist of (a) lifitegrast or a pharmaceutically acceptable salt thereof, (b) at least one semifluorinated alkane, and (c) at least one compound selected from Compound A1, Compound A2, Compound B, Compound C1, Compound C2, Compound C3, Compound D, and pharmaceutically acceptable salts thereof. The more preferred ophthalmic compositions may consist of (a) lifitegrast or a pharmaceutically acceptable salt thereof, (b) perfluorohexyloctane (F6H8), and (c) at least one compound selected from Compound A1, Compound A2, Compound B, Compound C1, Compound C2, Compound C3, Compound D, and pharmaceutically acceptable salts thereof.
[0061] The ophthalmic composition may comprise or consist essentially of: (a) from about 2% (w / w) to about 10% (w / w), for example about 2% (w / w) to about 6% (w / w), for example about 2.5% (w / w) or about 5% (w / w), lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis, (b) perfluorohexyloctane (F6H8), and (c) at least one compound selected from: Compound A1, Compound A2, Compound B, Compound C1, Compound C2, Compound C3, Compound D, and pharmaceutically acceptable salts thereof, wherein component (c) is present in the composition at up to about 0.5% by weight of the total composition. Preferably, F6H8 is the only semifluorinated alkane in the composition.
[0062] Preferably, the ophthalmic composition consists essentially of: (a) from about 2% (w / w) to about 10% (w / w), for example about 2% (w / w) to about 8% (w / w), for example about 2% (w / w) to about 6% (w / w), for example about 2.5% (w / w) or about 5% (w / w), lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis, (b) perfluorohexyloctane (F6H8), and (c) at least one compound selected from: Compound A1, Compound A2, Compound B, Compound C1, Compound C2, Compound C3, Compound D, and pharmaceutically acceptable salts thereof, wherein component (c) is present in the composition at up to about 0.5% by weight of the total composition. More preferably, the ophthalmic composition consists essentially of: (a)from about 2.5% (w / w) to about 5% (w / w) lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis, (b) perfluorohexyloctane (F6H8), and (c) at least one compound selected from: Compound A1, Compound A2, Compound B, Compound C1 , Compound C2, Compound C3, Compound D, and pharmaceutically acceptable salts thereof, wherein component (c) is present in the composition at up to about 0.5% by weight of the total composition.
[0063] Typically, the ophthalmic compositions are in the form of a liquid suspension. The lifitegrast or a pharmaceutically acceptable salt thereof is present as particles suspended in the semifluorinated alkane liquid, as lifitegrast is insoluble in semifluorinated alkanes.
[0064] Preferably, the ophthalmic compositions are stable liquid compositions. The ophthalmic compositions may be stable non-aqueous liquid compositions.
[0065] Preferably, the composition does not contain water or any pharmaceutically acceptable excipients.(a) Lifitegrast or a pharmaceutically acceptable salt thereof
[0066] The ophthalmic compositions of the present disclosure comprise lifitegrast or a pharmaceutically acceptable salt thereof. The lifitegrast in the composition may be in the form of a pharmaceutically acceptable salt, but is most preferably in the form of lifitegrast free acid. When lifitegrast is present in the form of a pharmaceutically acceptable salt, the pharmaceutically acceptable salt is preferably selected from sodium, potassium, arginine, and tris(hydroxymethyl)aminomethane salts, more preferably a sodium salt. Where a salt is used, concentrations or amounts of lifitegrast disclosed herein are calculated according to the corresponding quantity of lifitegrast free acid, i.e. on a free acid basis.
[0067] Lifitegrast or a pharmaceutically acceptable salt thereof may be included in the composition at a concentration from about 0.1% (w / w) to about 10% (w / w), for example, from about 1% (w / w) to about 10% (w / w), from about 2% (w / w) to about 10% (w / w), from about 2% (w / w) to about 8% (w / w), from about 2% (w / w) to about 6% (w / w), or from about 2.5% (w / w) to about 5% (w / w) on a free acid basis. Preferably, the concentration of lifitegrast is about 2.5% (w / w) or about 5% (w / w) on a free acid basis.(b) Semifluorinated alkanes
[0068] The ophthalmic compositions of the present disclosure comprise at least one semifluorinated alkane. Semifluorinated alkanes are linear or branched alkanes with fluorine atoms in place of some of the hydrogen atoms of the corresponding non-fluorinated alkane. In particular, semifluorinated alkanes are compounds composed of at least one perfluorinated hydrocarbon segment and at least one non-fluorinated hydrocarbon segment. According to a nomenclature used herein, the semifluorinated alkanes may be referred to as FnHm, wherein F refers to the perfluorinated hydrocarbon segment (F-segment), H refers to the non-fluorinated hydrocarbon segment (H-segment), and n and m refer to the number of carbon atoms of those segments, respectively. For example, F6H8 is used to refer to perfluorohexyloctane.
[0069] This type of nomenclature is typically used for compounds wherein the perfluorinated carbons are bonded together to form a single linear F-segment and the non-fluorinated carbons are bonded together to form a single linear H-segment. Typically, the perfluorinated F-segment is attached to an end of the non-fluorinated H-segment, i.e., it is attached to C1, so that the overall molecule is linear. However, a minority of branched compounds, wherein two linear (F and H) segments are joined at a different position such as C2, may be present. In the case of perfluorohexyloctane (F6H8), the perfluorohexyloctane comprises 95% (w / w) or more of 1 -perfluorohexyloctane, preferably 98% (w / w) or more, or more preferably 99.5% (w / w) or more. Preferably, the balance is 2-perfluorohexyloctane.
[0070] The at least one semifluorinated alkane may be included in the composition at a concentration of at least about 90% (w / w), for example, at least about 95% (w / w). The at least one semifluorinated alkane may be included in the composition at a concentration from about 90% (w / w) to about 99.5% (w / w), for example, from about 94% (w / w) to about 98% (w / w).
[0071] The at least one semifluorinated alkane may be chosen from F4H4, F4H5, F4H6, F4H7, F4H8, F5H4, F5H5, F5H6, F5H7, F5H8, F6H2, F6H4, F6H6, F6H7, F6H8, F6H9, F6H10, F6H12, F8H8, F8H10, F8H12, F10H10, or any combination thereof. The at least one semifluorinated alkane may be chosen from F4H4, F4H5, F4H6, F5H5, F5H6, F5H7, F5H8, F6H6, F6H7, F6H8, F6H9, F6H10, F8H8, F8H10, F8H12, F10H10, or any combination thereof. The at least one semifluorinated alkane may be chosen from F4H5, F4H6, F5H6, F5H7, F6H6, F6H7, F6H8, or any combination thereof. Preferably, the composition includes no more than two semifluorinated alkanes.
[0072] Preferably, the at least one semifluorinated alkane comprises at least one of perfluorohexyloctane (F6H8) and perfluorohexyldecane (F6H10). The at least one semifluorinated alkane may consist essentially of at least one of perfluorohexyloctane (F6H8) and perfluorohexyldecane (F6H10).
[0073] More preferably, the at least one semifluorinated alkane comprises perfluorohexyloctane (F6H8). Most preferably, the composition is substantially free of other semifluorinated alkanes besides F6H8. As used herein, a composition may be “substantially free of other semifluorinated alkanes” when the other semifluorinated alkanes are present at a relative amount of 2% (w / w) or less, preferably 1 % (w / w) or less, or more preferably 0.5% (w / w) or less based on the total amount of semifluorinated alkanes in the composition. Most preferably, the only semifluorinated alkane in the composition is F6H8.(c) Lifitegrast-related compounds
[0074] Disclosed herein is a compound selected from Compound A1, Compound A2, Compound B, Compound C1, Compound C2, Compound C3, and Compound D, and pharmaceutically acceptable salts of said compounds. These compounds are produced when I ifitegrast or a pharmaceutically acceptable salt thereof is subjected to gamma irradiation and can be used as standards for assessing the purity of gammairradiated lifitegrast.
[0075] The ophthalmic compositions can include at least one compound selected from Compound A1, Compound A2, Compound B, Compound C1, Compound C2, Compound C3, and Compound D. As the lifitegrast is preferably present in free acid form, these compounds are typically present in the composition in free acid form, but if the lifitegrast is present in the form of a pharmaceutically acceptable salt then these compounds would typically also be present in the form of a pharmaceutically acceptable salt. When any one of the compounds is present in the form of a pharmaceutically acceptable salt, the pharmaceutically acceptable salt is preferably selected from sodium, potassium, arginine, and tris(hydroxymethyl)aminomethane salts, more preferably a sodium salt. Where a salt is used, concentrations or amounts of component (c) disclosed herein are calculated according to the corresponding quantity of free acid, i.e. on a free acid basis.
[0076] Component (c) may be present in the composition at up to about 0.5% by weight of the total composition, preferably up to about 0.3% by weight of the total composition, or up to about 0.1% by weight of the total composition on a free acid basis. Component (c) may be present in the composition from about 0.0001 % to about 0.5% by weight of the total composition, from about 0.001% to about 0.3% by weight of the total composition, or from about 0.005% to about 0.1% by weight of the total composition on a free acid basis.
[0077] Components (a) and (c) together may be included in the composition at a total concentration from about 0.1% (w / w) to about 10% (w / w) on a free acid basis, forexample, from about 1% (w / w) to about 8% (w / w), from about 2% (w / w) to about 6% (w / w), or from about 2.5% (w / w) to about 5% (w / w). Preferably, the total concentration of components (a) and (c) is about 2.5% (w / w) or about 5% (w / w) on a free acid basis.
[0078] The total amount of component (c) (i.e. the total amount of compounds A1 , A2, B, C1, C2, C3 and D, or pharmaceutically acceptable salts thereof) present in the composition may be about 3 mol% or less relative to the amount of lifitegrast, for example, from about 0.1 mol% to about 3 mol % relative to the amount of lifitegrast. Preferably, the amount of component (c) is about 2 mol% or less relative to the amount of lifitegrast, for example, from about 0.5 mol% to about 2 mol% relative to the amount of lifitegrast.
[0079] The mole ratio of component (c) to lifitegrast may be about 3:97 or less, for example from about 0.1:99.9 to about 3:97. Preferably, the mole ratio of component (c) to lifitegrast is about 2:98 or less, for example from about 0.5:99.5 to about 2:98.
[0080] As will be understood by one of ordinary skill in the art, the relative amount, or mole ratio, of component (c) to lifitegrast may be determined by a high performance liquid chromatography (HPLC) method. The HPLC method may be performed with a UV-Vis detector. The method may be conducted at a temperature of 25°C using a (i) stationary phase with a particle size of 5 mm, (ii) a standard C18 (octadecylsilane) column with an internal diameter of 4.6 mm and a length of 250 mm, and (iii) a linear gradient system. Optionally, the mobile phase may consist of acetonitrile and 0.1% formic acid, and the detection wavelength may be set to 260 nm. The sample of sterilised lifitegrast to be analysed may be prepared by dissolving the sterilised lifitegrast in the mobile phase to obtain a concentration of 1 mg / ml.
[0081] As will be understood by one of ordinary skill in the art, the amount of each analyte is proportional to the peak area in the chromatogram attributed to that analyte. Thus, the amount of component (c) relative to lifitegrast is the same as the peak area for component (c) relative to the peak area for lifitegrast. When component (c) comprises more than one compound, the peak area for component (c) is the sum of the peak areas for each compound.
[0082] The ophthalmic composition may comprise or consist essentially of (a) lifitegrast or a pharmaceutically acceptable salt thereof, (b) at least one semifluorinated alkane, such as perfluorohexyloctane (F6H8), and (c) at least one compound selected from Compound B, Compound D, and pharmaceutically acceptable salts thereof.
[0083] The ophthalmic composition may comprise or consist essentially of (a) lifitegrast or a pharmaceutically acceptable salt thereof, (b) at least one semifluorinated alkane, such as perfluorohexyloctane (F6H8), and (c) at least one compound selected from Compound A1 , Compound A2, and pharmaceutically acceptable salts thereof. The mole ratio of Compound A1 to lifitegrast may be about 1.5:98.5 or less, for example, from about 0.1 :99.9 to about 1.5:98.5. The mole ratio of Compound A2 to lifitegrast may be about 1.5:98.5 or less, for example, from about 0.1:99.9 to about 1.5:98.5. The mole ratio of the combination of Compound A1 and Compound A2 to lifitegrast may be about 1.5:98.5 or less, for example, from about 0.1:99.9 to about 1.5:98.5.
[0084] The ophthalmic composition may comprise or consist essentially of (a) lifitegrast or a pharmaceutically acceptable salt thereof, (b) at least one semifluorinated alkane, such as perfluorohexyloctane (F6H8), and (c) Compound B, or a pharmaceutically acceptable salt thereof. The mole ratio of Compound B to lifitegrast may be about 0.5:99.5 or less, for example, from about 0.05:99.95 to about 0.5:99.5.
[0085] The ophthalmic composition may comprise or consist essentially of (a) lifitegrast or a pharmaceutically acceptable salt thereof, (b) at least one semifluorinated alkane, such as perfluorohexyloctane (F6H8), and (c) at least one compound selected from Compound C1, Compound C2, Compound C3, and pharmaceutically acceptable salts thereof. The mole ratio of Compound C1 to lifitegrast may be about 1:99 or less, for example, from about 0.1:99.9 to about 1:99. The mole ratio of Compound C2 to lifitegrast may be about 1 :99 or less, for example, from about 0.1:99.9 to about 1:99. The mole ratio of Compound C3 to lifitegrast may be about 1 :99 or less, for example, from about 0.1 :99.9 to about 1 :99. The mole ratio of the combination of Compound C1, Compound C2 and Compound C3 to lifitegrast may be about 1 :99 or less, for example, from about 0.1 :99.9 to about 1 :99.
[0086] The ophthalmic composition may comprise or consist essentially of (a) lifitegrast or a pharmaceutically acceptable salt thereof, (b) at least one semifluorinated alkane, such as perfluorohexyloctane (F6H8), and (c) Compound D or a pharmaceutically acceptable salt thereof. The mole ratio of Compound D to lifitegrast may be about 0.5:99.5 or less, for example, from about 0.05:99.95 to about 0.5:99.5.
[0087] The ophthalmic composition may comprise or consist essentially of: (a) lifitegrast or a pharmaceutically acceptable salt thereof, (b) at least one semifluorinated alkane, such as perfluorohexyloctane (F6H8), and (c):(i) at least one of Compound A1, Compound A2, and pharmaceutically acceptable salts thereof;(ii) Compound B or a pharmaceutically acceptable salt thereof;(iii) at least one of Compound C1, Compound C2, Compound C3, and pharmaceutically acceptable salts thereof; and(iv) Compound D or a pharmaceutically acceptable salt thereof.The mole ratio of component (c) to lifitegrast may be about 3:97 or less, for example, from about 0.5:99.5 to about 3:97.
[0088] Compound A1, Compound A2, Compound B, Compound C1, Compound C2, Compound C3, and Compound D can be characterised by their [M+H]+mass to charge ratio. Compound A1 and Compound A2 have a [M+H]+mass to charge ratio of 631.0697. Compound B has a [M+H]+mass to charge ratio of 619.0697. Compound C1, Compound C2 and Compound C3 have a [M+H]+mass to charge ratio of 613.0593. Compound D has a [M+H]+mass to charge ratio of 629.0541. The mass to charge ratio (m / z) is preferably measured by mass spectrometry.(d) Other components
[0089] Preferably, the ophthalmic compositions are substantially free of pharmaceutically acceptable excipients. As used herein, a composition may be “substantially free of pharmaceutically acceptable excipients” when excipients are present at an amount of 0.5% (w / w) or less, preferably 0.1% (w / w) or less, or more preferably 0.05% (w / w) or less, based on the total weight of the composition. The ophthalmic compositions may be free of pharmaceutically acceptable excipients.
[0090] The ophthalmic composition may be substantially free of medium chain triglycerides. Medium-chain triglycerides are triglycerides of fatty acids. The fatty acids have an aliphatic chain of 6-12 carbon atoms, and can be, for example, hexanoic acid, octanoic acid, decanoic acid, and dodecanoic acid. Therefore, a medium chain triglyceride may be a triglyceride of fatty acids, wherein the fatty acids comprise hexanoic acid, octanoic acid, decanoic acid, dodecanoic acid or combinations of two or more thereof. As used herein, a composition may be “substantially free of medium chain triglycerides” when medium chain triglycerides are present at an amount of 0.4% (w / w) or less, preferably 0.1% (w / w) or less, or more preferably 0.05% (w / w) or less, based on the total weight of the composition. The ophthalmic composition may be free of medium chain triglycerides.
[0091] Medium-chain triglycerides include coco-caprylate / caprate, propylene glycol dicaprylocaprate, glyceryl tricaprylate / tricaprate, and glyceryl tricaprylate / tricaprylin.Accordingly, the ophthalmic composition may be substantially free of coco-caprylate / caprate, propylene glycol dicaprylocaprate, glyceryl tricaprylate / tricaprate, and glyceryl tricaprylate / tricaprylin. As used herein, a composition may be “substantially free of coco-caprylate / caprate, propylene glycol dicaprylocaprate, glyceryl tricaprylate / tricaprate, and glyceryl tricaprylate / tricaprylin” when the combined amount of coco-caprylate / caprate, propylene glycol dicaprylocaprate, glyceryl tricaprylate / tricaprate, and glyceryl tricaprylate / tricaprylin present in the composition is 0.4% (w / w) or less, preferably 0.1% (w / w) or less, or more preferably 0.05% (w / w) or less, based on the total weight of the composition. The ophthalmic composition may be free of coco-caprylate / caprate, propylene glycol dicaprylocaprate, glyceryl tricaprylate / tricaprate, and glyceryl tricaprylate / tricaprylin.
[0092] The ophthalmic composition may be substantially free of semifluorinated alkyl alcohols. As used herein, a composition may be “substantially free of semifluorinated alkyl alcohols” when semifluorinated alkyl alcohols are present at an amount of 0.4% (w / w) or less, preferably 0.1% (w / w) or less, or more preferably 0.05% (w / w) or less, based on the total weight of the composition. The ophthalmic composition may be free of semifluorinated alkyl alcohols.
[0093] Preferably, the ophthalmic composition is substantially free of medium chain triglycerides and substantially free of semifluorinated alkyl alcohols. More preferably, the ophthalmic composition is free of medium chain triglycerides and free of semifluorinated alkyl alcohols.
[0094] The ophthalmic compositions may be sterile liquid compositions. The ophthalmic compositions may be sterile non-aqueous liquid compositions.
[0095] The formulation of lifitegrast or a pharmaceutically acceptable salt thereof may comprise one or more antioxidants to prevent oxidative degradation of the lifitegrast. The one or more antioxidants may comprise a thiosulfate salt, such as sodium thiosulfate. The antioxidants may comprise a metabisulfite salt. The antioxidants may comprise sodium bisulfate.
[0096] Other antioxidants which can be used to form pharmaceutical formulations include, but are not limited to, propyl, octyl and dodecyl esters of gallic acid, butylated hydroxyanisole (BHA, usually purchased as a mixture of ortho and meta isomers), green tea extract, uric acid, cysteine, pyruvate, nordihydroguaiaretic acid, ascorbic acid, salts of ascorbic acid such as ascorbyl palmitate and sodium ascorbate, ascorbyl glucosamine, vitamin E (i.e., tocopherols such as a-tocopherol), derivatives of vitamin E (e.g., tocopheryl acetate), retinoids such as retinoic acid, retinol, trans-retinol, cisretinol, mixtures of trans-retinol and cis-retinol, 3-dehydroretinol and derivatives ofvitamin A (e.g., retinyl acetate, retinal and retinyl palmitate, also known as tetinyl palmitate), sodium citrate, sodium sulfite, lycopene, anthocyanids, bioflavinoids (e.g., hesperitin, naringen, rutin and quercetin), superoxide dismutase, glutathione peroxidase, butylated hydroxytoluene (BHT), indole-3-carbinol, pycnogenol, melatonin, sulforaphane, pregnenolone, lipoic acid and 4-hydroxy-5-methyl-3[2H]-furanone. In the ophthalmic compositions of the present disclosure, one or more, or all, of the above antioxidants may be excluded, or may be present in less than effective amounts, either alone or in combination.
[0097] The amount of antioxidants present may be in the range of about 0.01-0.5% w / v. The amount of antioxidants present may be in the range of about 0.1 -about 0.5%, about 0.2-about 0.5%, about 0.3-about 0.5%, about 0.4-about 0.5%, about 0.01 -about 0.4%, about 0.1 -about 0.4%, about 0.2-about 0.4%, about 0.3-about 0.4%, about 0.01-about 0.3%, about 0.1 -about 0.3%, about 0.2-about 0.3%, about 0.01 -about 0.2%, about 0.1 -about 0.2%, or about 0.01 -about 0.1% w / v. Sodium thiosulfate may be present in an amount to provide antioxidant stability to the formulation, and the amount of sodium thiosulfate as a percentage by weight of all total antioxidants may be greater than 50% by weight.
[0098] Vitamin E and / or derivatives of vitamin E may be present in an amount to provide antioxidant stability to the formulation, and the amount of vitamin E and / or derivatives of vitamin E as a percentage by weight of all total antioxidants may be greater than 50% by weight.
[0099] The ophthalmic composition may further comprise a preservative. The preservative may be selected from benzalkonium chloride, cetrimonium, sodium perborate, stabilized oxychloro complex, polyquaternium-1 , chlorobutanol, edetate disodium, polyhexamethylene biguanide, a composition containing boric acid, sorbitol, propylene glycol, and zinc chloride (e.g., SofZia®), or combinations thereof.
[0100] The amount of preservative(s) present may be in the range of about 0.01-0.5% w / v. The amount of preservative(s) present may be in the range of about 0.1 -about 0.5%, about 0.2-about 0.5%, about 0.3-about 0.5%, about 0.4-about 0.5%, about 0.01 -about 0.4%, about 0.1 -about 0.4%, about 0.2-about 0.4%, about 0.3-about 0.4%, about 0.01 -about 0.3%, about 0.1 -about 0.3%, about 0.2-about 0.3%, about 0.01 -about 0.2%, about 0.1 -about 0.2%, or about 0.01 -about 0.1% w / v.
[0101] It is also possible, and preferred, to provide pharmaceutical formulations which are free from antioxidants, thus simplifying their preparation and avoiding potential irritation caused by antioxidant chemicals. The ability to maintain lifitegrast in stable form despite the absence of antioxidant is particularly surprising becauseoxygen is highly soluble in semifluorinated alkanes (and in particular in F6H8). The Xiidra product includes sodium thiosulfate as antioxidant.
[0102] It is also possible, and preferred, to provide pharmaceutical formulations which are free from preservatives even when they are provided in a multi-dose container, thus simplifying their preparation and avoiding potential irritation caused by known preservatives. Without wishing to be bound by theory, it is believed that the semifluorinated alkane can provide a preservative effect in the composition, in addition to providing a therapeutic ocular effect.
[0103] Thus, preferably, the ophthalmic compositions of the present disclosure are substantially free of antioxidants and / or substantially free of preservatives (save for semifluorinated alkanes, considering these as preservatives). Preferably, the ophthalmic compositions are substantially free of the antioxidants listed above and / or substantially free of the preservatives listed above. Further preferably, the ophthalmic compositions are substantially free of both antioxidants and preservatives. As used herein, a composition may be “substantially free of antioxidants” when antioxidants are present at an amount of 0.1% (w / w) or less, preferably 0.05% (w / w) or less, or more preferably 0.01% (w / w) or less. As used herein, a composition may be “substantially free of preservatives” when preservatives (save for semifluorinated alkanes, considering these as preservatives) are present at an amount of 0.1% (w / w) or less, preferably 0.05% (w / w) or less, or more preferably 0.01% (w / w) or less, based on the total weight of the composition. The ophthalmic compositions may be free of the antioxidants listed above and / or free of the preservatives listed above. More preferably, the ophthalmic compositions are free of both antioxidants and preservatives.
[0104] Preferably, the ophthalmic compositions are substantially free of water. As used herein, a composition may be “substantially free of water” when the composition comprises water at an amount of 1 % (w / w) or less, preferably 0.5% (w / w) or less, or more preferably 0.1% (w / w) or less, based on the total weight of the composition. The ophthalmic compositions may be free of water.Methods for treatment of ocular disorders
[0105] Further disclosed herein are methods for the treatment and / or temporary prevention of at least one ocular disorder, comprising administering to a patient in need thereof an effective amount of an ophthalmic composition as described above comprising components (a) to (c).
[0106] Similarly, provided are: ophthalmic compositions as described above comprising components (a) to (c), for use in a method for the treatment or temporary prevention of at least one ocular disorder.
[0107] Further provided is (a) lifitegrast or a pharmaceutically acceptable salt thereof and (b) at least one semifluorinated alkane for use in the manufacture of a medicament for the treatment or temporary prevention of at least one ocular disorder, preferably dry eye disease, wherein the medicament is an ophthalmic composition as described above comprising components (a) to (c).
[0108] The at least one ocular disorder may include, but is not limited to, dry eye disease, dry eye, meibomian gland dysfunction, adult chlamydial ophthalmia, ocular rosacea presbyopia, recalcitrant recurrent corneal erosions, ocular cicatricial pemphigoid, Sjogren’s syndrome (SS), non-SS keratoconjunctivitis sicca (KCS), conjunctivitis, allergic conjunctivitis, endophthalmitis, keratitis, uveitis, styes, eye inflammation, eye discomfort or pain, itching of the eye, inflammatory dry eye, redness of the eye, watery eye, stinging or burning of the eye, gritty sensation of the eye, eye sensitivity to light, blurred vision, more frequent blinking, pressure behind the eye, eyelids that are greasy, crusty, itchy, swollen or sticking, and the like.
[0109] The at least one ocular disorder may be chosen from dry eye disease, dry eye, meibomian gland dysfunction, adult chlamydial ophthalmia, ocular rosacea presbyopia, recalcitrant recurrent corneal erosions, ocular cicatricial pemphigoid, Sjogren’s syndrome (SS), non-SS keratoconjunctivitis sicca (KCS), conjunctivitis, allergic conjunctivitis, endophthalmitis, keratitis, uveitis, or any combination thereof.
[0110] The at least one ocular disorder may be chosen from conjunctivitis, keratitis, dry eye disease, or any combination thereof.
[0111] Preferably, the at least one ocular disorder is dry eye disease. The ophthalmic composition is particularly suitable for the treatment of dry eye disease and in particular for the treatment of mixed-type dry eye disease where the patient suffers from both aqueous deficient dry eye disease and evaporative dry eye disease, due to the presence of both lifitegrast and at least one semifluorinated alkane. The dry eye disease may be aqueous deficient dry eye disease. The dry eye disease may be evaporative dry eye disease. The dry eye disease may be both aqueous deficient dry eye disease and evaporative dry eye disease.
[0112] The dry eye disease may have hyperosmolarity as a cause and / or as a symptom. The dry eye disease may have tear film instability as a cause and / or as asymptom. The dry eye disease may have both hyperosmolarity and tear film instability as a cause and / or as a symptom.
[0113] The method may comprise administering an effective amount of the ophthalmic composition in the form of one, two, three, or four droplets in each eye, preferably an effective amount of the ophthalmic composition in the form of one or two droplets in each eye, more preferably an effective amount of the ophthalmic composition in the form of one droplet in each eye.
[0114] The method may comprise administering the ophthalmic composition in each eye one, two, three, or four times daily. Preferably, the method may comprise administering the ophthalmic composition in each eye twice daily. This represents a reduced dosing frequency compared to an ophthalmic composition where perfluorohexyloctane is the sole active ingredient (Miebo™), which is typically administered four times daily.
[0115] Thus, the method may preferably comprise administering an effective amount of the ophthalmic composition in the form of one or two droplets in each eye one, two, three, or four times daily. More preferably, the method may comprise administering an effective amount of the ophthalmic composition in the form of one droplet in each eye twice daily.
[0116] The ophthalmic composition may be administered for at least 4 days, preferably for at least 10 days from the same multi-dose container closure system. Due to the preservative effect of the semifluorinated alkane and the resulting stability of the ophthalmic composition, the composition can be provided in a multi-dose container closure system without the addition of potentially irritating preservatives or antioxidants. This is more convenient to the user than a single dose unit and generates less packaging waste.
[0117] Preferably, the ophthalmic composition is administered from the same multidose container closure system twice daily in each eye for at least 4 days, more preferably for at least 10 days.
[0118] The examples support that ophthalmic compositions containing at least about 2% (w / w) lifitegrast will have good clinical efficacy against dry eye disease and will result in comparable or greater exposure of lifitegrast in the bulbar conjunctiva and cornea than a comparative aqueous solution. Thus, preferably, the method of treatment and / or temporary prevention of at least one ocular disorder, especially dry eye disease, comprises administering to a patient in need thereof an effective amount of an ophthalmic composition described above, wherein the lifitegrast or apharmaceutically acceptable salt thereof is included in the composition at a concentration from about 2% (w / w) to about 6% (w / w), for example from about 2.5% (w / w) to about 5% (w / w), on a free acid basis. More preferably, the composition administered in the method consists essentially of: (a) about 2% (w / w) to about 6% (w / w), for example from about 2.5% (w / w) to about 5% (w / w), lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis, (b) perfluorohexyloctane (F6H8), and (c) at least one compound selected from Compound A1, Compound A2, Compound B, Compound C1, Compound C2, Compound C3, and Compound D, and pharmaceutically acceptable salts thereof, wherein component (c) is present in the composition at up to about 0.5% by weight of the total composition.Container closure system
[0119] Further disclosed herein is a container closure system, such as system comprising a bottle or a vial, containing an ophthalmic composition as described above. The container closure system may be a multi-dose container closure system. The container closure system may comprise or consist essentially of polypropylene.BRIEF DESCRIPTION OF DRAWINGS
[0120] Figure 1 shows cumulative lifitegrast concentrations (pg / g) in EpiCorneal™ tissue after 4 hours.
[0121] Figure 2 shows the concentration (ng / g) of lifitegrast measured in cornea over time (0-8 hours).
[0122] Figure 3 shows the LIPLC chromatogram for unsterilised lifitegrast free acid measured using UV radiation at 260 nm.
[0123] Figure 4 shows the LIPLC chromatogram for gamma-sterilised lifitegrast free acid measured using UV radiation at 260 nm.EXAMPLESExample 1: Sterilisation of lifitegrast
[0124] The inventors found that a sterile filtration process is not feasible for compositions comprising lifitegrast and a semifluorinated alkane because lifitegrast is not soluble in the semifluorinated alkane liquid and is therefore present as particles in suspension. A standard sterile filtration process removes any particles with a particle diameter of greater than 0.22 pm, which is most of the lifitegrast particles in a typical composition of the invention. Therefore, sterile filtration results in a high percentage loss of active ingredient. Moreover, the milling required to obtain a lifitegrast particlediameter suitable for sterile filtration is energy intensive and unnecessary for the efficacy of the final composition.
[0125] The inventors have further found that I ifitegrast cannot be sterilised by heat due to its low melting point between 125 and 130°C. At the temperatures of around 150 to 180°C required for effective heat sterilisation, the lifitegrast melts and resolidifies into large aggregates which are unsuitable for further processing, such as ball milling, and which are unsuitable for ophthalmic compositions since they would cause a feeling of grittiness in the eye.
[0126] The inventors found that gas sterilisation using ethylene oxide is feasible but is not favoured due to the risks to human health and the environment associated with this toxic gas.
[0127] Thus, during the manufacture of ophthalmic compositions comprising lifitegrast and a semifluorinated alkane, lifitegrast may be advantageously sterilised using gamma irradiation, as shown in the following example. This sterilisation method was found to be more effective for the sterilisation of lifitegrast and more environmentally friendly than other known methods.Example 2: Gamma irradiated lifitegrast
[0128] Three samples of lifitegrast free acid, each having a bioburden of <10 CFU / g, were sterilised using gamma irradiation at doses of 17.0 kGy, 22.1 kGy, and 36.9 kGy, respectively.
[0129] The sterilised samples and a control of unsterilised lifitegrast free acid were analysed using HPLC. The chromatogram of the irradiated samples showed four peaks that were not present in the chromatogram of the unsterilized control sample. These peaks correspond to compounds labelled A-D formed during the gamma sterilisation process. The retention time and relative peak area values were as follows:Control Low Med High Gamma Irradiation Dose(0 kGy) (17.0 kGy) (22.1 kGy) (36.9 kGy) RelativeRetentionName Retention %Area (HPLC)Time (min)Time (min)Compound A 28.91 0.74 - 0.40 0.54 0.79 Compound B 29.38 0.76 - 0.12 0.16 0.21 Compound D 30.74 0.79 - 0.13 0.18 0.22 Compound C 34.21 0.88 - 0.23 0.31 0.46Lifitegrast 38.90 1 99.8 98.3 97.82 96.94 Other impurities 0.2 0.82 0.99 1.38 Total impurities 0.2 1.70 2.18 3.06
[0130] Compounds A-D are present after irradiation at all three doses. As expected, as the radiation dose increases, the level of these compounds also increases. The structures of the compounds A-D were investigated further using ultra performance liquid chromatography-ultraviolet detection-mass spectrometry (UPLC-UV-MS).
[0131] A new sample of lifitegrast free acid was sterilised using gamma irradiation at doses of from 30 to 40 kGy. The sterilised sample and a control sample of unsterilised lifitegrast free acid were analysed using LIPLC. The analytes were detected by UV radiation at 260 nm. Figure 3 shows the chromatogram for the control sample. Figure 4 shows the chromatogram for the gamma-sterilised sample, and includes additional peaks formed during the gamma irradiation process. The peaks attributed to compounds A-D are the four largest peaks by area, excluding the lifitegrast peak. The retention time, relative peak area, and mass to charge ratio (m / z) values were as follows:Compound Retention time (min) % Area (UPLC) [M+H]+(m / z) A 5.87 0.73 631.0697 B 6.17 0.29 619.0697 C 7.09 0.46 613.0593D 7.59 0.31 629.0541
[0132] Peak mapping was performed based on elution order and relative peak area. The following molecular structures were determined for compounds A-D based on the best fit elemental composition. The delta from theory (i.e., difference between the theoretical mass to charge ratio and experimentally observed mass to charge ratio) was calculated. For impurities A and C, it was not possible to confirm a single molecular structure with total confidence, but instead the molecular structure for these impurities was narrowed down to two or three possibilities (Compound A1 or Compound A2; Compound C1 , Compound C2 or Compound C3).
[0133] The results for compound A were as follows:Compound A[M+H]+631.0697Best fit elemental composition C29H25O8N2CI2SDelta from theory -0.60 ppmAlteration from lifitegrast +1 O0HO^ Cl, - , abs\ — |\|(-| \ .( hl r-' / p / ° HOZ( yo Possible structures OHO-# Cl / abs\ — <0 \JK J? '.S. ° Cl >=< \ \7°h <Q^° Name(s) (2S)-2-(2-(benzofuran-6-carbonyl)- 5.7-dichloro-4-hydroxy-1 ,2,3,4- tetrahydroisoquinoline-6- carboxam ido)-3-(3- (methylsulfonyl)phenyl)propanoic acid(2S)-2-(2-(benzofuran-6-carbonyl)- 5.7-dichloro-3-hydroxy-1 ,2,3,4- tetrahydroisoquinoline-6- carboxam ido)-3-(3- (methylsulfonyl)phenyl)propanoicacid
[0134] The results for compound B were as follows:Compound B[M+H]+619.0697Best fit elemental composition C28H25O8N2CI2SDelta from theory -0.97 ppmAlteration from lifitegrast -1 ring double bond (RDB), -1 C, +1 OStructure 0HO^f Cl- abs\ — NM ) - \ / \ y w oo) — ' O N~#"'s. Cl —ZV-A / 0 (\— / OHV-H 0 Name(s) (S)-2-(5,7-dichloro-2-(4-formyl-3- hydroxybenzoyl)-1 ,2,3,4- tetrahydroisoquinoline-6- carboxam ido)-3-(3- (methylsulfonyl)phenyl)propanoicacid
[0135] The results for compound C were as follows:Compound C[M+H]+629.0541Best fit elemental composition C29H23O8N2CI2SDelta from theory -0.84 ppmAlteration from lifitegrast +1 ring double bond (RDB), +1 0, - H2 Possible structures 0HOy a / ==\ absy — NH \ — O0. r0W Mcis' ° Q-o □HOy ci> - < abs) — NH / - \j o. r ° W / 0<T0HO-# Cl / =\ aby— NH \ — A0. 0 wNy"s- cix\Name(s) (S)-2-(2-(benzofuran-6-carbonyl)-5,7- dichloro-1 -oxo-1 ,2,3,4- tetrahydroisoquinoline-6-carboxam ido)-3-(3-(methylsulfonyl)phenyl)propanoicacid(S)-2-(2-(benzofuran-6-carbonyl)-5,7- dichloro-4-oxo-1 ,2,3,4- tetrahydroisoquinoline-6- carboxam ido)-3-(3- (methylsulfonyl)phenyl)propanoicacid(S)-2-(2-(benzofuran-6-carbonyl)-5,7- dichloro-3-oxo-1 ,2,3,4- tetrahydroisoquinoline-6- carboxam ido)-3-(3- (methylsulfonyl)phenyl)propanoicacid
[0136] The results for compound D were as follows:Compound D[M+H]+619.0697Best fit elemental composition C28H25O8N2CI2SDelta from theory -0.68 ppmAlteration from lifitegrast -1 ring double bond (RDB), -1 C, +1 O Structure 0Ho4 ClZ=\ abA--N|-| \ — ,4 r M / 0. / 0 / N\Clx— / / ° / VV= / 0HVH0 Name(s) (S)-2-(2-(benzofuran-6-carbonyl)-5,7- dichloro-1 ,2-dihydroisoquinoline-6- carboxam ido)-3-(3- (methylsulfonyl)phenyl)propanoicacid
[0137] The safety of all structures was verified by in silico assessment.
[0138] The sterilised lifitegrast obtained after irradiation with gamma radiation may be mixed aseptically with at least one sterilised semifluorinated alkane to form a sterile ophthalmic composition for use in the treatment and / or temporary prevention of dry eye disease. The above analysis shows that lifitegrast sterilised by gamma irradiation contains compounds having the structures shown above. Thus, compositions comprising lifitegrast sterilised by this method will also contain these compounds, and the compounds are useful standards for assessing the purity of gamma-irradiated lifitegrast.
[0139] It is shown in the examples of PCT / EP2024 / 082568 that stable, sterile suspensions of lifitegrast free acid and perfluorohexyloctane (F6H8) useful in the treatment and / or temporary prevention of dry eye disease can be obtained without the addition of a preservative or antioxidant. It is further shown that these suspensions achieve similar ocular exposure as aqueous lifitegrast solutions at only one third of the dose. The F6H8 used in the following examples consisted essentially of 1 -perfluorohexyloctane and less than 0.5% (w / w) of 2-perfluorohexyloctane.Example 3: F6H8 preservative activity
[0140] The antimicrobial properties of F6H8 were evaluated according to the Ph. Eur.5.1.3 method. Results were as follows:Organism Time Count Log reduction Inoculum 2 x 105- 0 hour 16 4.1S. aureus 6 hours 0 5.324 hours 0 5.328 days 0 5.3 Inoculum 8 x 105- 0 hour 5 x 1041.2P. aeruginosa 6 hours 4 x 1023.324 hours 8 5.028 days 0 5.9 Inoculum 2 x 105- 0 hour 2 x 1041.0E. coli 6 hours 0 5.324 hours 0 5.328 days 0 5.3 Inoculum 9 x 105- 0 hour 5 x 1032.3C. albicans7 days 0 6.028 days 0 6.0 Inoculum 7 x 105- 0 hour 8 x 1040.9A. brasiliensis7 days 1 x 1032.828 days 2 x 1032.5
[0141] F6H8 meets the acceptance criteria for this assay, namely that (a) the concentrations of viable bacteria show not less than a 2 log reduction from the initialcalculated count at 6 hours, not less than a 3 log reduction at 24 hours, and no recovery at 28 days and (b) the concentrations of yeasts and molds show not less than a 2 log reduction from the initial calculated count at 7 days, with no increase at 28 days. Thus F6H8 meets the antimicrobial effectiveness requirements without the need for extrinsic preservative.
[0142] This result can be explained by the lack of water activity in the F6H8 liquid. Addition of solid lifitegrast introduces no water activity and so this mixture also will not support microbial growth.Example 4: Suspensions
[0143] Lifitegrast free acid was added to F6H8 in various proportions, including (w / w) 0.25%, 1%, 2%, 2.5%, 4%, 5%, and 10%. The lifitegrast is in soluble in F6H8 and forms a suspension. When left standing the lifitegrast settles to form a sediment.
[0144] Lifitegrast is stable in the suspensions. During storage at 40°C levels of lifitegrast in a 4% suspension ( / .e. 96% (w / w) F6H8, 4% (w / w) lifitegrast) did not change:Time (months) 0 1 3Lifitegrast (%) 99.87 99.87 99.89
[0145] Similar results were seen in a 2% suspension. No significant impurities were seen when stored at 25°C for 3 months. A minor impurity increase was seen after 3 months at 40°C, but it was insignificant. Thus lifitegrast and F6H8 are chemically compatible. The same compatibility can be expected with other semifluorinated alkanes as they do not include any additional reactive groups.
[0146] Lifitegrast / F6H8 suspensions were supplemented with a-tocopherol or tocopheryl acetate as antioxidants (e.g. 2% lifitegrast, 93% F6H8, 5% tocopheryl acetate). After storage for 1 month at 40°C levels of lifitegrast-derived impurities showed no significant differences with or without the antioxidants (e.g. for a 2% emulsion with 5% tocopheryl acetate the level of lifitegrast was 99.92% at time zero and still after 3 months at 40°C). Oxidation-derived degradation products were not detected with or without antioxidant. Lifitegrast and F6H8 are therefore compatible, without needing addition of any antioxidant.
[0147] Suspensions with 2% or 5% lifitegrast were subjected to centrifugation for 1 hour at 500, 750 or 1000 rpm to accelerate settling of the lifitegrast powder, and the ease and efficiency of redispersibility were evaluated by shaking the settled product by hand (conditions to mimic patient use). After 500 rpm centrifugation the powdercould be resuspensed by one gentle inversion. After 750 or 1000 rpm centrifugation resuspension required several gentle inversions or shaking by hand 2 or 3 times. Thus the suspensions show redispersibility which is acceptable for patient use.
[0148] Suspensions were filled into polypropylene bottles with a dropper outlet and droplets were weighed. Droplets of F6H8 alone had a mass of 15.91 mg with a standard deviation of 0.55 mg, with a volume of 11.35 pL. Droplets of the 5% I ifitegrast suspension weighed 15.93 mg with a standard deviation of 0.43 mg, with a volume of 11.85 pL. Droplets of the suspensions thus show acceptable dose uniformity within a bottle, and lifitegrast does not interfere with the ability of F6H8 to form droplets.
[0149] Droplets of the F6H8 suspension are ~3x smaller than the aqueous droplets of Xiidra™ (5% lifitegrast solution), and so the amount of lifitegrast delivered by a single droplet of 5% suspension is lower than the amount delivered by a single Xiidra™ droplet.Example 5: Ocular irritation assessment
[0150] The ocular tolerability of lifitegrast free acid / F6H8 suspensions (5%) were assessed, including evaluation of sting / burn reactions relative to the marketed lifitegrast solution (Xiidra™) and the marketed F6H8 product (Miebo™). NZW rabbits (3 per group) received topical ocular doses QID for 5 Days (40 pL / dose = 160 pL / eye / day). Ocular irritation was assessed by (a) macroscopic examination (Draize scoring) after the fourth daily dose and, if irritation was noted, again in the following morning and (b) microscopic examination by slit lamp and indirect ophthalmoscopy at days 0 & 5. Sting / burn assessments were taken after the second and fourth daily dose, recording the cumulative duration of blinking / squinting and also noting other indicators (e.g., rubbing).
[0151] The suspensions were well tolerated with no toxicologically significant findings after 5 days of dosing.
[0152] The maximum weighted score for irritation in any animal was scored as 4 out of a maximum of 110. Suspensions were well tolerated and any negative effects (redness, discharge, conjunctival congestion) were short-lived and did not increase in seventy over the duration of the study.Example 6: Epicorneal tissue model
[0153] The EpiComeal 3D human tissue model (MatTek) provides a predictive non-animal model for assessing ophthalmic drug delivery. This model was used to assess the effect of F6H8 on lifitegrast permeability and the dose-dependence of permeability characteristics.
[0154] Seven formulations were tested: four suspensions (0.25%, 1 %, 2.5% and 5%), a second 1% suspension, and two aqueous solutions (1% and 5%). 12 pL volumes were administered to the model and assessed for permeability (collecting 200 pL samples from the receiver at 15, 30, 60, 120, 180 and 240 minutes to measure penetrated lifitegrast concentration) and for lifitegrast concentration in EpiCorneal tissue after 240 minutes.
[0155] Suspensions had lower lifitegrast permeability than solutions but higher tissue accumulation. A dose-dependent increase in tissue accumulation was observed from 0.25% to 2.5% with the suspensions. Figure 1 shows cumulative lifitegrast concentrations in EpiCorneal tissue after 4 hours, indicating that the two 1% suspensions provided about the same performance as a 5% aqueous solution, and the 5% suspension provided higher tissue accumulation than the 5% solution. Slower permeation into the receiver using the suspensions might be explained by the need for the solid lifitegrast to dissolve before it can permeate.Example 7: Ocular pharmacokinetic study
[0156] An in vivo pharmacokinetic study was used to evaluate dose-dependent ocular bioavailability of lifitegrast free acid / F6H8 suspensions in dutch belted rabbits. Four suspensions were tested (10%, 5%, and 2x 1%) and compared to a 5% aqueous solution:Cone. (%w / w)Ingredient5% sol" 1 % susp" 5% susp" 10% susp" Lifitegrast 5 1 5 10 Perfluorohexyloctane - 99 95 90 Sodium chloride 0.3 - - - Sodium thiosulfate 0.29 - - - Sodium phosphate - - - 0.35dibasicSodium hydroxide - - - 7.49(1 N) solutionPurified water q.s. - - -
[0157] The dosage volume per eye was 12 pL for the suspensions and 35 pL for the solution. Samples of cornea, bulbar conjunctiva, aqueous humor, anterior sclera, and palpebra conjunctiva were taken after 0.25, 1 , 3, and 8 hours. Corneal results are shown in Figure 2.
[0158] Dose-proportional ocular exposure of lifitegrast was seen with suspensions from 1-5%, with a higher than proportional increase in exposure at 10%.
[0159] Areas under the lifitegrast concentration-time curve from 0 to 8 hours (AUCo-8hr) were calculated with linear trapezoidal linear interpolation method using WinNonlin. Values were as follows, relative to the aqueous solution (100%):5% sol" 1% SUSP" 1% SUSP" 5% susp" 10% susp" Cornea 100 11 9 77 148 B.conj 100 36 28 212 642 P.conj 100 27 17 150 552 Aq humor 100 14 13 55 309Sclera 100 13 15 60 195
[0160] The 5% suspension dose at 12 pL gave the most similar ocular exposure to 5% solution dosed at 35 pL. Thus the administered amount of lifitegrast can be reduced 3-fold while achieving the same ocular exposure.
[0161] Maximum observed concentration (Cmax) values were determined relative to the aqueous solution (100%):5% sol" 1% susp" 1% susp" 5% susp" 10%susp" Cornea 100 10 10 72 115 B.conj 100 36 68 216 706 P.conj 100 27 30 179 525Aq humor 100 14 18 115 688Sclera 100 21 35 132 177
[0162] The 5% suspension in F6H8 achieved an approximately two-fold increase in Cmax and AUCo-shr in the conjunctiva, despite the total dose of lifitegrast being about one third of the dose administered with the 5% aqueous solution (due to the difference in droplet size). Without being bound by theory, the conjunctiva is an important tissue in the pathology of dry eye disease because it is the site of mucin-secreting goblet cells, which are important for tear film quality and can be damaged by inflammation. Moreover, the conjunctiva is believed to be the primary site of immune cells on the ocular surface, which makes it a likely primary site of action for lifitegrast. Therefore, the increase in Cmax and AUCo-shr in the conjunctiva means that the total dose of lifitegrast can be lowered (e.g., by using a smaller drop of a similar dose-strength) while delivering more of the drug to the presumed primary site of action.Example 8: Human pharmacokinetic modelling data
[0163] A nonparametric superpositioning (NSP) method implemented in Pheonix WinNonlin software was used to model single dose pharmacokinetic data from rabbits and to simulate steady state drug exposure at the human conjunctiva and cornea based on those data.
[0164] The model used the following lifitegrast concentration data in the bulbar conjunctiva and cornea of rabbits following administration of a single drop of 12 pL of a suspension of 5% (w / w) and 1% (w / w) lifitegrast in F6H8 or 35 pL of an aqueous solution of 5% (w / w) lifitegrast. The difference in drop size means that the delivered dose of lifitegrast from a single drop of the aqueous solution is more than double the dose of lifitegrast from a single drop of the suspension for the same concentration of lifitegrast. The data relating to 1% and 5% lifitegrast / F6H8 suspensions were used to simulate steady state drug exposure of 1%, 1.5%, 2%, 2.5% and 5% suspensions in humans dosed with a 12 pL drop BID for 3 days. The data relating to 5% lifitegrast aqueous solution were used to simulate steady state drug exposure of 0.1%, 1% and 5% aqueous solutions in humans dosed with a 35 pL drop BID for 3 days. The conversion involved multiplying the exposure in rabbits by 40% to convert the exposure values to expected exposure in humans.Lifitegrast concentrations in B. conjunctiva and cornea in rabbits following a single drop of 12 L of a suspension ora single drop of 35 pL of a solution Concentration (ng / g)Tissue Formulation0.25 1 h 3 h 8 h5% Solution 18300 7200* 19400 6690 B. Conj 1% Suspension 6100 2240* 6910 28205 % Suspension 41900 41900 24700 21800 5% Solution 7020 5130 4930 2240 Cornea 1 % Suspension 666.7 471.3 641.6 197.35 % Suspension 5040 3060 4280 1570‘Handled as outliers. The outliers were removed and imputed with extrapolated values based on first order elimination.
[0165] The model makes the following assumptions:• Each dose acts independently• There is no change in absorption between doses• There is no change in clearance between doses• Linear kinetics apply (dose proportionality)
[0166] The following results predict exposure in human bulbar conjunctiva at steady state:Formulation Cmax (ng / g) Ctau (ng / g) AUCtau (ng -h / g) 5% Suspension 10416 3840 755005% Solution 9321 1910 636832.5% Suspension 5208 1920 377502% Suspension 4179 1536 302081.5% Suspension 3134 1152 226561% Suspension 3547 969 260261% Solution 1864 382 12737Note: Cmax, Ctau and AUCtau of LIF in human B. conjunctiva were obtained in the simulated profile between 60 to 72 hours.
[0167] The following results predict exposure in human cornea at steady state: Formulation Cmax (ng / g) Ctau (ng / g) AUCtau (ng-h / g) 5% Suspension 2498 579 157225% Solution 3394 720 203652.5% Suspension 1249 290 78612% Suspension 1030 232 64891.5% Suspension 485 88 29931% Suspension 313 59 19951% Solution 679 144 4073Note: Cmax, Ctau and AUCtau of LIF in human cornea were obtained in the simulated profile between 60 to 72 hours.
[0168] Both 1% and 5% aqueous solutions of lifitegrast are known to have clinical efficacy, as reported in Semba et al. Am J Ophthalmol, 2012;153:1050-1060. Therefore, results relating to the suspension that show a comparable or higher exposure to lifitegrast than the results relating to the 1% and 5% aqueous solutions are also expected to be clinically efficacious.
[0169] In the bulbar conjunctiva, which is believed to be a primary site of action of lifitegrast, the simulated results for the 5% suspension surprisingly predict greater exposure than for the 5% aqueous solution, and likewise, the simulated results for the 1-2.5% suspensions predict greater exposure than the 1% aqueous solution. This is even more surprising given the smaller drop size, and therefore smaller dose of lifitegrast, for the suspensions compared to the aqueous solutions. For the same reasons, it was also surprising that the simulated results for 2-2.5% suspensionspredict greater exposure in the cornea, which is also an important site of action for lifitegrast, than for the 1% aqueous solution. This data therefore indicates that suspensions of lifitegrast in F6H8, and in particular suspensions containing at least about 2% (w / w) lifitegrast (e.g., suspensions comprising about 2% (w / w) to about 6% (w / w) lifitegrast), will have good clinical efficacy and result in comparable or greater exposure of lifitegrast in the bulbar conjunctiva and cornea than a higher dose of the aqueous solution at the same concentration.
[0170] It will be understood that the invention has been described by way of example only and modifications may be made whilst remaining within the scope and spirit of the invention.NUMBERED EMBODIMENTSA process for preparing an ophthalmic composition comprising (a) lifitegrast or a pharmaceutically acceptable salt thereof and (b) at least one semifluorinated alkane, the process comprising:(i) sterilising lifitegrast or a pharmaceutically acceptable salt thereof using gamma irradiation; and(ii) mixing the sterilised lifitegrast or a pharmaceutically acceptable salt thereof with at least one semifluorinated alkane.The process of numbered embodiment 1 , wherein the lifitegrast or a pharmaceutically acceptable salt thereof is exposed to a dose of gamma radiation of from 10 to 50 kGy, for example from 15 to 40 kGy.The process of embodiment 1 or embodiment 2, wherein the process is a process for preparing an ophthalmic composition consisting essentially of (a) lifitegrast or a pharmaceutically acceptable salt thereof and (b) at least one semifluorinated alkane.The process of any one of embodiments 1-3, wherein the process is a process for preparing an ophthalmic composition consisting essentially of (a) lifitegrast or a pharmaceutically acceptable salt thereof and (b) perfluorohexyloctane (F6H8), the process comprising:(i) sterilising lifitegrast or a pharmaceutically acceptable salt thereof using gamma irradiation; and(ii) mixing the sterilised lifitegrast or a pharmaceutically acceptable salt thereof with perfluorohexyloctane (F6H8).An ophthalmic composition comprising (a) lifitegrast or a pharmaceutically acceptable salt thereof, (b) at least one semifluorinated alkane, and (c) at least one compound selected from:Compound A1:Compound A2:Compound B:Compound C1:Compound C2:Compound C3:Compound D:and pharmaceutically acceptable salts thereof.The ophthalmic composition of numbered embodiment 5, wherein component (c) is present at up to about 0.5% by weight of the total composition on a free acid basis, for example from about 0.0001 % to about 0.5% by weight of the total composition.The ophthalmic composition of numbered embodiment 5 or numbered embodiment 6, wherein component (c) is present at up to about 0.3% by weight of the total composition on a free acid basis, for example from about 0.001 % to about 0.3% by weight of the total composition.The ophthalmic composition of any one of numbered embodiments 5-7, wherein component (c) is present at up to about 0.1 % by weight of the total composition on a free acid basis, for example from about 0.005% to about 0.1 % by weight of the total composition.The ophthalmic composition of any one of numbered embodiments 5-8, wherein the mole ratio of component (c) to lifitegrast is about 3:97 or less, for example from about 0.1 :99.9 to about 3:97.The ophthalmic composition of any one of numbered embodiments 5-9, wherein the mole ratio of component (c) to lifitegrast is about 2:98 or less, for example from about 0.5:99.5 to about 2:98.The ophthalmic composition of any one of numbered embodiments 5-10, wherein the total amount of component (c) present in the composition is about 3 mol% or less relative to the amount of lifitegrast or a pharmaceutically acceptable salt thereof, for example from about 0.1 mol% to about 3 mol% relative to the amount of lifitegrast or a pharmaceutically acceptable salt thereof. The ophthalmic composition of any one of numbered embodiments 5-11 , wherein the total amount of component (c) is about 2 mol% or less relative to the amount of lifitegrast or a pharmaceutically acceptable salt thereof, for example from about 0.5 mol% to about 2 mol% relative to the amount of lifitegrast or a pharmaceutically acceptable salt thereof.The ophthalmic composition of any one of numbered embodiments 5-12, wherein the composition comprises (a) lifitegrast or a pharmaceutically acceptable salt thereof, (b) at least one semifluorinated alkane, and (c) at least one compound selected from Compound B, Compound D, and pharmaceutically acceptable salts thereof.The ophthalmic composition of any one of numbered embodiments 5-12, wherein the composition comprises (a) lifitegrast or a pharmaceutically acceptable salt thereof, (b) at least one semifluorinated alkane, and (c) at least one compound selected from Compound A1 , Compound A2, and pharmaceutically acceptable salts thereof.The ophthalmic composition of numbered embodiment 14, wherein the mole ratio of component (c) to lifitegrast is about 1.5:98.5 or less, for example from about 0.1 :99.9 to about 1.5:98.5.The ophthalmic composition of any one of numbered embodiments 5-12, wherein the composition comprises (a) lifitegrast or a pharmaceutically acceptable salt thereof, (b) at least one semifluorinated alkane, and (c) Compound B or a pharmaceutically acceptable salt thereof.The ophthalmic composition of numbered embodiment 16, wherein the mole ratio of component (c) to lifitegrast is about 0.5:99.5 or less, for example from about 0.05:99.95 to about 0.5:99.5.The ophthalmic composition of any one of numbered embodiments 5-12, wherein the composition comprises (a) lifitegrast or a pharmaceutically acceptable salt thereof, (b) at least one semifluorinated alkane, and (c) at least one compound selected from Compound C1, Compound C2, Compound C3, and pharmaceutically acceptable salts thereof.The ophthalmic composition of numbered embodiment 18, wherein the mole ratio of component (c) to lifitegrast is about 1 :99 or less, for example from about 0.1 :99.9 to about 1 :99.The ophthalmic composition of any one of numbered embodiments 5-12, wherein the composition comprises (a) lifitegrast or a pharmaceutically acceptable salt thereof, (b) at least one semifluorinated alkane, and (c) Compound D or a pharmaceutically acceptable salt thereof.The ophthalmic composition of numbered embodiment 20, wherein the mole ratio of component (c) to lifitegrast is about 0.5:99.5 or less, for example from about 0.05:99.95 to about 0.5:99.5.The ophthalmic composition of any one of numbered embodiments 5-21 , wherein the composition comprises: (a) lifitegrast or a pharmaceutically acceptable salt thereof, (b) at least one semifluorinated alkane, and (c)(i) at least one of Compound A1, Compound A2, and pharmaceutically acceptable salts thereof;(ii) Compound B or a pharmaceutically acceptable salt thereof;(iii) at least one of Compound C1, Compound C2, Compound C3, and pharmaceutically acceptable salts thereof; and(iv) Compound D or a pharmaceutically acceptable salt thereof.The ophthalmic composition of numbered embodiment 22, wherein the mole ratio of component (c) to lifitegrast is about 3:97 or less, for example from about 0.5:99.5 to about 3:97.The ophthalmic composition of any one of numbered embodiments 5-23, wherein the composition consists essentially of: (a) lifitegrast or apharmaceutically acceptable salt thereof, (b) at least one semifluorinated alkane, and (c) at least one compound selected from Compound A1 , Compound A2, Compound B, Compound C1, Compound C2, Compound C3, and Compound D, and pharmaceutically acceptable salts thereof.The ophthalmic composition of any one of numbered embodiments 5-24, wherein the composition consists essentially of: (a) lifitegrast or a pharmaceutically acceptable salt thereof, (b) at least one semifluorinated alkane, and (c) at least one compound selected from Compound A1 , Compound A2, Compound B, Compound C1, Compound C2, Compound C3, and Compound D, and pharmaceutically acceptable salts thereof.The ophthalmic composition of any one of numbered embodiments 5-25, wherein no more than two semifluorinated alkanes are present.The ophthalmic composition of any one of numbered embodiments 5-26, wherein the composition consists essentially of: (a) lifitegrast or a pharmaceutically acceptable salt thereof, (b) no more than two semifluorinated alkanes, and (c)(i) at least one of Compound A1 , Compound A2, and pharmaceutically acceptable salts thereof;(ii) Compound B or a pharmaceutically acceptable salt thereof;(iii) at least one of Compound C1, Compound C2, Compound C3, and pharmaceutically acceptable salts thereof; and(iv) Compound D or a pharmaceutically acceptable salt thereof.The ophthalmic composition of any one of numbered embodiments 5-27, wherein the composition consists of: (a) lifitegrast or a pharmaceutically acceptable salt thereof, (b) no more than two semifluorinated alkanes, and (c) (i) at least one of Compound A1 , Compound A2, and pharmaceutically acceptable salts thereof;(ii) Compound B or a pharmaceutically acceptable salt thereof;(iii) at least one of Compound C1, Compound C2, Compound C3, and pharmaceutically acceptable salts thereof; and(iv) Compound D or a pharmaceutically acceptable salt thereof.The ophthalmic composition of any one of numbered embodiments 5-27, wherein the composition consists essentially of: (a) lifitegrast or a pharmaceutically acceptable salt thereof, (b) perfluorohexyloctane (F6H8), and (c)(i) at least one of Compound A1 , Compound A2, and pharmaceutically acceptable salts thereof;(ii) Compound B or a pharmaceutically acceptable salt thereof;(iii) at least one of Compound C1, Compound C2, Compound C3, and pharmaceutically acceptable salts thereof; and(iv) Compound D or a pharmaceutically acceptable salt thereof.The ophthalmic composition of any one of numbered embodiments 5-29, wherein the composition consists of: (a) lifitegrast or a pharmaceutically acceptable salt thereof, (b) perfluorohexyloctane (F6H8), and (c)(i) at least one of Compound A1 , Compound A2, and pharmaceutically acceptable salts thereof;(ii) Compound B or a pharmaceutically acceptable salt thereof;(iii) at least one of Compound C1, Compound C2, Compound C3, and pharmaceutically acceptable salts thereof; and(iv) Compound D or a pharmaceutically acceptable salt thereof.The ophthalmic composition of any one of numbered embodiments 5-30, or the process of any one of numbered embodiments 1-4, wherein the at least one semifluorinated alkane is chosen from F4H4, F4H5, F4H6, F4H7, F4H8, F5H4, F5H5, F5H6, F5H7, F5H8, F6H2, F6H4, F6H6, F6H7, F6H8, F6H9, F6H10, F6H12, F8H8, F8H10, F8H12, F10H10, or any combination thereof; for example wherein the composition includes no more than two semifluorinated alkanes. The ophthalmic composition of any one of numbered embodiments 5-28 and 29, or the process of any one of numbered embodiments 1-4 and 31 , wherein the at least one semifluorinated alkane comprises at least one of perfluorohexyloctane (F6H8) and perfluorohexyldecane (F6H10).The ophthalmic composition of any one of numbered embodiments 5-28 and 29-30, or the process of any one of numbered embodiments 1-4 and 31-32, wherein the at least one semifluorinated alkane comprises perfluorohexyloctane (F6H8). The ophthalmic composition of any one of numbered embodiments 5-33, or the process of any one of numbered embodiments 1-4 and 31-33, wherein the composition comprises perfluorohexyloctane (F6H8) and is substantially free of other semifluorinated alkanes.The ophthalmic composition of any one of numbered embodiments 5-34, or the process of any one of numbered embodiments 1-4 and 31-34, wherein the lifitegrast is in the form of lifitegrast free acid.The ophthalmic composition of any one of numbered embodiments 5-35, or the process of any one of numbered embodiments 1-4 and 31-35, wherein the lifitegrast or a pharmaceutically acceptable salt thereof is included in the composition at a concentration from about 0.1% (w / w) to about 10% (w / w) on a free acid basis.The ophthalmic composition of any one of numbered embodiments 5-36, or the process of any one of numbered embodiments 1-4 and 31-36, wherein the lifitegrast or a pharmaceutically acceptable salt thereof is included in the composition at a concentration from about 1% (w / w) to about 8% (w / w) on a free acid basis.The ophthalmic composition of any one of numbered embodiments 5-37, or the process of any one of numbered embodiments 1-4 and 31-37, wherein the lifitegrast or a pharmaceutically acceptable salt thereof is included in the composition at a concentration from about 2% (w / w) to about 8% (w / w), for example about 2% (w / w) to about 6% (w / w), on a free acid basis.The ophthalmic composition of any one of numbered embodiments 5-38, wherein the composition consists essentially of: (a) from about 2% (w / w) to about 8% (w / w), for example about 2% (w / w) to about 6% (w / w), lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis,(b) perfluorohexyloctane (F6H8), and (c) at least one compound selected from Compound A1, Compound A2, Compound B, Compound C1, Compound C2, Compound C3, and Compound D, and pharmaceutically acceptable salts thereof, wherein component (c) is present in the composition at up to about 0.5% by weight of the total composition.The ophthalmic composition of any one of numbered embodiments 5-39, or the process of any one of numbered embodiments 1-4 and 31-38, wherein the lifitegrast or a pharmaceutically acceptable salt thereof is included in the composition at a concentration from about 2.5% (w / w) to about 5% (w / w) on a free acid basis.The ophthalmic composition of any one of numbered embodiments 5-40, wherein the composition consists of: (a) from about 2.5% (w / w) to about 5% (w / w) lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis, (b) perfluorohexyloctane (F6H8), and (c) at least one compound selected from Compound A1, Compound A2, Compound B, Compound C1, Compound C2, Compound C3, and Compound D, and pharmaceutically acceptable salts thereof, wherein component (c) is present in the composition at up to about 0.5% by weight of the total composition.The ophthalmic composition of any one of numbered embodiments 5-41 , or the process of any one of numbered embodiments 1-4, 31-38 and 40, wherein the lifitegrast or a pharmaceutically acceptable salt thereof is included in the composition at a concentration of about 2.5% (w / w) on a free acid basis.The ophthalmic composition of any one of numbered embodiments 5-41 , or the process of any one of numbered embodiments 1-4, 31-38 and 40, wherein the lifitegrast or a pharmaceutically acceptable salt thereof is included in the composition at a concentration of about 5% (w / w) on a free acid basis.The ophthalmic composition of any one of numbered embodiments 5-43, wherein the composition consists essentially of: (a) about 2.5% (w / w) or about 5% (w / w) lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis, (b) perfluorohexyloctane (F6H8), and (c) at least one compound selected from Compound A1, Compound A2, Compound B, Compound C1, Compound C2, Compound C3, and Compound D, and pharmaceutically acceptable salts thereof, wherein component (c) is present in the composition at up to about 0.5% by weight of the total composition.The ophthalmic composition of any one of numbered embodiments 5-44, wherein the composition consists of: (a) about 2.5% (w / w) or about 5% (w / w) lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis, (b) perfluorohexyloctane (F6H8), and (c) at least one compound selected from Compound A1, Compound A2, Compound B, Compound C1, Compound C2, Compound C3, and Compound D, and pharmaceutically acceptable salts thereof, wherein component (c) is present in the composition at up to about 0.5% by weight of the total composition.The ophthalmic composition of any one of numbered embodiments 5-45, or the process of any one of numbered embodiments 1-4, 31-38, 40 and 42-43, wherein the composition is in the form of a liquid suspension.The ophthalmic composition of any one of numbered embodiments 5-46, or the process of any one of numbered embodiments 1-4, 31-38, 40, 42-43 and 46, wherein the composition is at least one of (i) substantially free of medium chain triglycerides and (ii) substantially free of semifluorinated alkyl alcohols, preferably wherein the composition is free of medium chain triglycerides and free of semifluorinated alkyl alcohols.The ophthalmic composition of any one of numbered embodiments 5-47, or the process of any one of numbered embodiments 1-4, 31-38, 40, 42-43 and 46-47, wherein the composition is at least one of (i) substantially free of an antioxidant and (ii) substantially free of a preservative.The ophthalmic composition of any one of numbered embodiments 5-48, or the process of any one of numbered embodiments 1-4, 31-38, 40, 42-43 and 46-48, wherein the composition is substantially free of water.A container closure system comprising the composition as defined in any one of numbered embodiments 5-49.A method for the treatment or temporary prevention of at least one ocular disorder comprising administering to a patient in need thereof an effective amount of the ophthalmic composition as defined in any one of numbered embodiments 5-49.The method according to numbered embodiment 51 , wherein the at least one ocular disorder is chosen from dry eye disease, dry eye, meibomian gland dysfunction, adult chlamydial ophthalmia, ocular rosacea presbyopia, recalcitrant recurrent corneal erosions, ocular cicatricial pemphigoid, Sjogren’s syndrome (SS), non-SS keratoconjunctivitis sicca (KCS), conjunctivitis, allergic conjunctivitis, endophthalmitis, keratitis, uveitis, styes, eye inflammation, eye discomfort or pain, itching of the eye, inflammatory dry eye, redness of the eye, watery eye, stinging or burning of the eye, gritty sensation of the eye, eye sensitivity to light, blurred vision, more frequent blinking, pressure behind the eye, eyelids that are greasy, crusty, itchy, swollen or sticking, or any combination thereof.The method according to numbered embodiment 51 or numbered embodiment 52, wherein the at least one ocular disorder is chosen from dry eye disease, dry eye, meibomian gland dysfunction, adult chlamydial ophthalmia, ocular rosacea presbyopia, recalcitrant recurrent corneal erosions, ocular cicatricial pemphigoid, Sjogren’s syndrome (SS), non-SS keratoconjunctivitis sicca (KCS), conjunctivitis, allergic conjunctivitis, endophthalmitis, keratitis, uveitis, or any combination thereof.The method according to any one of numbered embodiments 51-53, wherein the at least one ocular disorder is chosen from conjunctivitis, keratitis, dry eye disease, or any combination thereof.The method according to any one of numbered embodiments 51-54, wherein the at least one ocular disorder is dry eye disease, preferably wherein the at least one ocular disorder is evaporative dry eye disease and aqueous deficient dry eye disease.The method according to any one of numbered embodiments 51-55, wherein the method comprises administering to a patient in need thereof an effective amount of the ophthalmic composition as defined in any one of numbered embodiments 5-49, wherein the I ifitegrast or a pharmaceutically acceptable salt thereof isincluded in the composition at a concentration from about 2% (w / w) to about 6% (w / w), for example from about 2.5% (w / w) to about 5% (w / w), on a free acid basis.An ophthalmic composition obtained by the process of any one of numbered embodiments 1-4, 31-38, 40, 42-43 and 46-49.A process for preparing an ophthalmic composition comprising or consisting essentially of (a) I ifitegrast or a pharmaceutically acceptable salt thereof and (b) at least one semifluorinated alkane, preferably wherein the semifluorinated alkane is F6H8, the process comprising:(i) obtaining a sample of a batch of sterilised lifitegrast or a pharmaceutically acceptable salt thereof;(ii) determining that the total amount of Compound A1 , Compound A2, Compound B, Compound C1, Compound C2, Compound C3, and Compound D, and pharmaceutically acceptable salts thereof present in the sample is about 3 mol% or less relative to the amount of lifitegrast or a pharmaceutically acceptable salt thereof;(iii) mixing the batch of sterilised lifitegrast or a pharmaceutically acceptable salt thereof with at least one semifluorinated alkane. A process for assessing a batch of an ophthalmic composition comprising or consisting essentially of (a) lifitegrast and (b) at least one semifluorinated alkane, preferably wherein the semifluorinated alkane is F6H8, the process comprising:(i) obtaining a sample of the batch of ophthalmic composition;(ii) determining the total amount of Compound A1 , Compound A2, Compound B, Compound C1, Compound C2, Compound C3, and Compound D, and pharmaceutically acceptable salts thereof present in the sample; and(iii) validating the batch of ophthalmic composition only if the total amount of said compounds is about 3 mol% or less relative to the amount of lifitegrast or a pharmaceutically acceptable salt thereof.A compound selected from Compound A1, Compound A2, Compound B, Compound C1, Compound C2, Compound C3, and Compound D, and pharmaceutically acceptable salts thereof.
Claims
CLAIMS1. A process for preparing an ophthalmic composition comprising (a) lifitegrast or a pharmaceutically acceptable salt thereof and (b) at least one semifluorinated alkane, the process comprising:(i) sterilising lifitegrast or a pharmaceutically acceptable salt thereof using gamma irradiation; and(ii) mixing the sterilised lifitegrast or a pharmaceutically acceptable salt thereof with at least one semifluorinated alkane.
2. The process of claim 1 , wherein the lifitegrast or a pharmaceutically acceptable salt thereof is exposed to a dose of gamma radiation of from 10 to 50 kGy, for example from 15 to 40 kGy.
3. The process of claim 1 or claim 2, wherein the process is a process for preparing an ophthalmic composition consisting essentially of (a) lifitegrast or a pharmaceutically acceptable salt thereof and (b) at least one semifluorinated alkane.
4. The process of any one of claims 1 -3, wherein the process is a process for preparing an ophthalmic composition consisting essentially of (a) lifitegrast or a pharmaceutically acceptable salt thereof and (b) perfluorohexyloctane (F6H8), the process comprising:(i) sterilising lifitegrast or a pharmaceutically acceptable salt thereof using gamma irradiation; and(ii) mixing the sterilised lifitegrast or a pharmaceutically acceptable salt thereof with perfluorohexyloctane (F6H8).
5. An ophthalmic composition comprising (a) lifitegrast or a pharmaceutically acceptable salt thereof, (b) at least one semifluorinated alkane, and (c) at least one compound selected from:Compound A1:Compound A2:Compound B:Compound C1:Compound C2:Compound C3:Compound D:and pharmaceutically acceptable salts thereof.
6. The ophthalmic composition of claim 5, wherein component (c) is present at up to about 0.3% by weight of the total composition on a free acid basis, for example from about 0.001 % to about 0.3% by weight of the total composition.
7. The ophthalmic composition of claim 5 or claim 6, wherein the total amount of component (c) present in the composition is about 3 mol% or less relative to the amount of lifitegrast or a pharmaceutically acceptable salt thereof, for example from about 0.1 mol% to about 3 mol% relative to the amount of lifitegrast or a pharmaceutically acceptable salt thereof.
8. The ophthalmic composition of any one of claims 5-7, wherein the composition consists essentially of: (a) lifitegrast or a pharmaceutically acceptable salt thereof, (b) at least one semifluorinated alkane, and (c) at least one compound selected from Compound A1, Compound A2, Compound B, Compound C1, Compound C2, Compound C3, and Compound D, and pharmaceutically acceptable salts thereof.
9. The ophthalmic composition of any one of claims 5-8, wherein the composition consists essentially of: (a) lifitegrast or a pharmaceutically acceptable salt thereof, (b) no more than two semifluorinated alkanes, and (c)(i) at least one of Compound A1 , Compound A2, and pharmaceutically acceptable salts thereof;(ii) Compound B or a pharmaceutically acceptable salt thereof;(iii) at least one of Compound C1, Compound C2, Compound C3, and pharmaceutically acceptable salts thereof; and(iv) Compound D or a pharmaceutically acceptable salt thereof.
10. The ophthalmic composition of any one of claims 5-9, or the process of any one of claims 1-4, wherein the composition comprises perfluorohexyloctane (F6H8) and is substantially free of other semifluorinated alkanes.
11. The ophthalmic composition of any one of claims 5-10, wherein the composition consists essentially of: (a) lifitegrast or a pharmaceutically acceptable salt thereof, (b) perfluorohexyloctane, and (c)(i) at least one of Compound A1 , Compound A2, and pharmaceutically acceptable salts thereof;(ii) Compound B or a pharmaceutically acceptable salt thereof;(iii) at least one of Compound C1, Compound C2, Compound C3, and pharmaceutically acceptable salts thereof; and(iv) Compound D or a pharmaceutically acceptable salt thereof.
12. The ophthalmic composition of any one of claims 5-11 , or the process of any one of claims 1-4 and 10, wherein the lifitegrast or a pharmaceutically acceptable salt thereof is included in the composition at a concentration from about 0.1% (w / w) to about 10% (w / w) on a free acid basis.
13. The ophthalmic composition of any one of claims 5-12, wherein the composition consists essentially of: (a) from about 2% (w / w) to about 8% (w / w), for example about 2% (w / w) to about 6% (w / w), lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis, (b) perfluorohexyloctane (F6H8), and (c) at least one compound selected from Compound A1, Compound A2, Compound B, Compound C1, Compound C2, Compound C3, and Compound D, and pharmaceutically acceptable salts thereof, wherein component (c) is present in the composition at up to about 0.5% by weight of the total composition.
14. The ophthalmic composition of any one of claims 5-13, or the process of any one of claims 1-4, 10 and 12, wherein the lifitegrast or a pharmaceutically acceptable salt thereof is included in the composition at a concentration from about 2% (w / w) to about 6% (w / w), for example from about 2.5% (w / w) to about 5% (w / w), on a free acid basis.
15. The ophthalmic composition of any one of claims 5-14, wherein the composition consists essentially of: (a) from about 2.5% (w / w) to about 5% (w / w) lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis,(b) perfluorohexyloctane (F6H8), and (c) at least one compound selected from Compound A1, Compound A2, Compound B, Compound C1, Compound C2, Compound C3, and Compound D, and pharmaceutically acceptable salts thereof, wherein component (c) is present in the composition at up to about 0.5% by weight of the total composition.
16. The ophthalmic composition of any one of claims 5-15, or the process of any one of claims 1-4, 10, 12 and 14, wherein the lifitegrast is in the form of lifitegrast free acid.
17. The ophthalmic composition of any one of claims 5-16, or the process of any one of claims 1-4, 10, 12, 14 and 16, wherein the composition is at least one of (i) substantially free of medium chain triglycerides and (ii) substantially free of semifluorinated alkyl alcohols, preferably wherein the composition is free of medium chain triglycerides and free of semifluorinated alkyl alcohols.
18. The ophthalmic composition of any one of claims 5-17, or the process of any one of claims 1-4, 10, 12, 14 and 16-17, wherein the composition is at least one of (i) substantially free of an antioxidant and (ii) substantially free of a preservative.
19. A container closure system comprising the composition as defined in any one of claims 5-18.
20. A method for the treatment or temporary prevention of at least one ocular disorder comprising administering to a patient in need thereof an effective amount of the ophthalmic composition as defined in any one of claims 5-19.
21. The method according to claim 20, wherein the at least one ocular disorder is chosen from dry eye disease, dry eye, meibomian gland dysfunction, adult chlamydial ophthalmia, ocular rosacea presbyopia, recalcitrant recurrent corneal erosions, ocular cicatricial pemphigoid, Sjogren’s syndrome (SS), non-SS keratoconjunctivitis sicca (KCS), conjunctivitis, allergic conjunctivitis, endophthalmitis, keratitis, uveitis, styes, eye inflammation, eye discomfort or pain, itching of the eye, inflammatory dry eye, redness of the eye, watery eye, stinging or burning of the eye, gritty sensation of the eye, eye sensitivity to light, blurred vision, more frequent blinking, pressure behind the eye, eyelids that are greasy, crusty, itchy, swollen or sticking, or any combination thereof.
22. The method according to claim 20 or claim 21 , wherein the at least one ocular disorder is dry eye disease, preferably wherein the at least one ocular disorder is evaporative dry eye disease and aqueous deficient dry eye disease.
23. The method according to any one of claims 20-22, wherein the method comprises administering to a patient in need thereof an effective amount of the ophthalmic composition as defined in any one of claims 5-19, wherein the I ifitegrast or a pharmaceutically acceptable salt thereof is included in the composition at a concentration from about 2% (w / w) to about 6% (w / w), for example from about 2.5% (w / w) to about 5% (w / w), on a free acid basis.
24. An ophthalmic composition obtained by the process of any one of claims 1-4, 10, 12, 14 and 16-18.
25. A process for preparing an ophthalmic composition comprising or consisting essentially of (a) I ifitegrast or a pharmaceutically acceptable salt thereof and (b) at least one semifluorinated alkane, preferably wherein the semifluorinated alkane is F6H8, the process comprising:(i) obtaining a sample of a batch of sterilised lifitegrast or a pharmaceutically acceptable salt thereof;(ii) determining that the total amount of Compound A1 , Compound A2, Compound B, Compound C1, Compound C2, Compound C3, and Compound D, and pharmaceutically acceptable salts thereof present in the sample is about 3 mol% or less relative to the amount of lifitegrast or a pharmaceutically acceptable salt thereof;(iii) mixing the batch of sterilised lifitegrast or a pharmaceutically acceptable salt thereof with at least one semifluorinated alkane.
26. A process for assessing a batch of an ophthalmic composition comprising or consisting essentially of (a) lifitegrast and (b) at least one semifluorinated alkane, preferably wherein the semifluorinated alkane is F6H8, the process comprising:(i) obtaining a sample of the batch of ophthalmic composition;(ii) determining the total amount of Compound A1 , Compound A2, Compound B, Compound C1 , Compound C2, Compound C3, and Compound D, and pharmaceutically acceptable salts thereof present in the sample; and(iii) validating the batch of ophthalmic composition only if the total amount of said compounds is about 3 mol% or less relative to the amount of I ifitegrast or a pharmaceutically acceptable salt thereof.
27. A compound selected from Compound A1, Compound A2, Compound B, Compound C1 , Compound C2, Compound C3, and Compound D, and pharmaceutically acceptable salts thereof.
